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ABSTRACT 
Diabetes mellitus is a disorder of inadequate insulin action and consequent 
high blood glucose levels. Type 2 diabetes accounts for the majority of cases of the 
disease and is characterized by insulin resistance and relative insulin deficiency 
resulting in metabolic deregulation. It is a complex disorder to treat as its 
pathogenesis is not fully understood and involves a variety of defects including ~-cell 
failure, insulin resistance in the classic target tissues (adipose, muscle, liver), as well 
as defects in a-cells and kidney, brain, and gastrointestinal tissue. Present oral 
treatments, which aim at mimicking the effects of insulin, remain limited in their 
efficacy and therefore the study of the effects of novel compounds on insulin target 
tissues is an important area of research both for potentially finding more treatment 
options as well as for increasing our knowledge of metabolic regulation in health and 
disease. 
In recent years the extensively studied polyphenol, resveratrol, has been 
reported to have antidiabetic effects showing that it increases glucose uptake by 
skeletal muscle cells and prevents fatty acid-induced insulin resistance in vitro and in 
vivo. Naringenin, a citrus flavonoid with structural similarities to resveratrol, is 
reported to have antioxidan.t, antiproliferative, anticancer, and anti-inflammatory 
properties. Effects on glucose and lipid metabolism have also been reported including 
blood glucose and lipid lowering effects. However, whether naringenin has insulin-
like effects is not clear. In the present study the effects of naringenin on glucose 
uptake in skeletal muscle cells are examined and compared with those of insulin. 
Naringenin treatment of L6 myotubes increased glucose uptake in a dose- and time-
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dependent manner and independent of insulin. The effects of naringenin on glucose 
uptake achieved similar levels as seen with maximum insulin stimulation and its 
effect was additive with sub-maximal insulin treatment. Like insulin naringenin 
treatment did not increase glucose uptake in myoblasts. To elucidate the mechanism 
involved in naringenin action we looked at its effect on phosphatidylinositol 3-kinase 
(PI3K) and Akt, two signalling molecules that are involved in the insulin signalling 
cascade leading to glucose uptake. Naringenin did not stimulate basal or insulin-
stimulated Akt phosphorylation but inhibition of PI3K by wortmannin partially 
repressed the naringenin-induced glucose uptake. We also examined naringenin's 
effect on AMP-activated protein kinase (AMPK), a molecule that is involved in 
mediating glucose uptake by a variety of stimuli. Naringenin stimulated AMPK 
phosphorylation and this effect was not inhibited by wortmannin. To deduce the 
nature of the naringenin-stimulated AMPK phosphorylation and its impact on glucose 
uptake we examined the role of several molecules implicated in mod.ulating AMPK 
activity including SIRTl, LKB 1, and ca2+ Icalmodulin-dependent protein kinase 
kinase (CaMKK). 
Our results indicate that inhibition of SIRTI did not prevent the naringenin-
stimulated glucose uptake Of. AMPK phosphorylation; naringenin did not stimulate 
LKB 1 phosphorylation; and inhibition of CaMKK did not prevent naringenin-
stimulated glucose uptake. Inhibition of AMPK by compound C also did not prevent 
naringenin-stimulated glucose uptake but effectively inhibited the phosphorylation of 
AMPK suggesting that AMPK may not be required for the naringenin-stimulated 
glucose uptake. 
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CHAPTER 1: INTRODUCTION 
1.1 Insulin 
Insulin is a protein hormone produced by the ~ cells of the endocrine portion 
of the pancreas, the islets of Langerhans. Upon binding to its receptor on target cells 
insulin activates signalling cascades that lead to diverse biological effects including 
glucose and lipid uptake and metabolism, gene expression, protein synthesis, and cell 
growth, division and survival (55,99). Of its many roles insulin is particularly 
important in maintaining glucose homeostasis. When the blood glucose level 
becomes elevated the change is detected by the pancreas, which responds by releasing 
insulin into the blood stream. Insulin helps to bring high blood glucose levels back to 
normal by inhibiting liver glycogenolysis and gluconeogenesis, by stimulating entry 
of glucose into tissue targets such as skeletal muscle, adipose and cardiac muscle, and 
promoting glycogen synthesis (Figure 1) (99,102). 
Glucose is a crucial source of energy for the body and due to being a vital 
source for some tissues the body favours the utilization of other fuels, and storage of 
glucose unless stores are high in order to maintain consistent blood glucose levels. It 
is therefore important to have an effective system regulating blood glucose. Insulin is 
critical in this process as it f<;lcilitates the transport of glucose into target cells for 
utilization and storage when blood glucose levels increase. Glucose is a polar 
carbohydrate with five hydroxyl groups and it cannot pass through the hydrophobic 
plasma membranes of cells. With some exceptions it is transported into cells through 
facilitated diffusion by specialized glucose transporter proteins called GLUTs that 
open a gateway for glucose entry. There are 14 different GLUT isoforms the most 
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studied of which are GLUTs 1-4, and these transporters exhibit tissue specific 
expression. Although there are certain constitutive GLUTs present on the plasma 
membrane of all cells in the body, they cannot sufficiently maintain normoglycemia 
of the ever-changing environment. GLUT1 is one such transporter, which is largely 
responsible for glucose transport under basal conditions (55,102). 
However, once blood glucose levels become elevated the glucose transporters 
available on plasma membranes are not sufficient to remove the glucose from the 
blood. Therefore the body requires more glucose transporters in order to increase the 
permeability of the plasma membrane to glucose and the success of achieving this 
largely depends on the availability of the GLUT4 transporters in cells that express the 
GLUT4 transport gene. The availability of GLUT4 transporters at the plasma 
membrane, unlike that of other glucose transporters, is mainly regulated by insulin. 
Glucose transport via this system is primarily confined to muscle and adipose cells 
(55,99). In cardiac muscle, skeletal muscle and adipose tissue the insulin signal leads 
to the translocation of GLUT4 proteins from intracellular stores to the plasma 
membrane thereby increasing glucose transport into the tissues (4.1,112). GLUT4-
containing vesicles continuously cycle from intracellular stores to the plasma 
membrane but insulin stimulation increases the rate of GLUT4-vesicle exocytosis and 
reduces the rate of edocytosis thus leading to more GLUT4 transporters at the plasma 
membrane (56.1,102). Skeletal muscle accounts for the majority, ~80%, of the 
insulin-stimulated glucose uptake, which makes this tissue an important component 
of glucose homeostasis (53,85). 
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Figure 1: Role of insulin in maintaining blood glucose levels. An increase in blood 
glucose levels occurs after a meal which will stimulate the pancreas to release 
insulin into the circulation. Major insulin targets include the liver, adipose tissue, 
and skeletal muscle. Insulin inhibits glycogenolysis and gluconeogenesis in the 
liver, and stimulates muscle and adipose tissue glucose uptake and glycogen 
synthesis. 
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1.2 The Insulin Receptor 
The insulin receptor is a plasma membrane intrinsic tyrosine kinase receptor 
and is part of a subfamily of receptor tyrosine kinases, which also includes the 
insulin-like growth factor (IGF)-I receptor and the insulin receptor-related receptor 
(IRR) (l02). The receptor is composed of two monomers; an a and a ~ subunit linked 
together by a disulfide bond. The two monomers are linked by two disulfide bridges 
between the two a subunits (10). The a subunits are entirely localized in the 
extracellular fluid and contain the insulin-binding domain while the ~ subunits start at 
the extracellular fluid, span the plasma membrane, and extend into the cytosolic 
surface where the tyrosine kinase is located. The intrinsic tyrosine kinase activity of 
the insulin receptor is essential for insulin action (99). The precise mechanism of 
insulin action on glucose uptake remains elusive but parts of the signalling pathway 
have been well established (Figure 2). In the unbound state the a subunit inhibits the 
tyrosine kinase activity of the ~ subunit. Upon binding to the a subunits of its receptor 
insulin removes this suppression of the kinase activity which is followed by 
autophosphorylation of the ~ subunits and conformational changes of the receptor 
leading to increased activity of the intrinsic tyrosine kinase domain of the receptor 
(102). The phosphorylated tyrQsine residues of the insulin receptor recruit a variety of 
intracellular downstream target proteins. At least nine of these downstream targets 
have been identified of which four belong to a family of insulin receptor substrate 
(IRS) proteins while the remaining include Gab-1, p60dok, Cbl, APS, and isoforms of 
Shc (102). 
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1.3 IRS 
The IRS family of proteins consists of at least four isoforrns (IRS-1 to -4), 
which differ in their tissue distribution, cellular localization and function. The role of 
IRS-1 in metabolic regulation is mainly focused in skeletal muscle and adipose tissue 
and includes involvement in protein synthesis and glucose transport. The IRS-2 is 
expressed in liver, adipose, and muscle tissue where it has a broad range of activity, 
the IRS-3 is predominantly expressed in adipose tissue and the IRS-4 in 
neuroendocrine tissue. Although the elucidation of the respective role(s) ofIRS-3 and 
IRS-4 proteins is not complete studies suggest that they may negatively regulate IRS-
1 and -2 (99,102). Phosphorylated tyrosine residues of the IRS proteins act as docking 
sites for a range of downstream effector proteins that contain a Src-homology-2 
(SH2) such as phosphatidylinositol 3-kinase (PI3K), growth factor receptor binding 
protein 2 (Grb-2), and SH2-containing protein-tyrosine phosphatase-2 (SHP-2) 
(99,102). The specific insulin response generated by a cell depends on which of these 
downstream effector molecules are expressed and which of them are recruited to the 
phosphorylated IRS protein (99). 
1.4 PI3K 
PI3K is composed of a p 110 catalytic subunit and a p85 regulatory subunit 
that has two SH2 domains which interact with specific phosphotyrosine-containing 
motifs in the IRS proteins, pYMXM and pYXXM (5,102). There are eight isoforrns 
of p85 regulatory subunit identified which are derived from three genes. The isoforrn 
that is believed to be responsible for mediating most responses is p85a (102). PI3K is 
activated when the SH2 domain of its p85-regulatory subunit binds to the 
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phosphorylated tyrosine residues located on substrates such as IRS-I. Upon binding 
PI3K becomes active and it catalyses the phosphorylation of 3' -phosphoinositides to 
produce phosphatidylinosi tol-3 -phosphates, particularly 
Phosphatidylinositol-3-phosphate binds to the pleckstrin homology (PH) domains of 
various molecules resulting in alteration of their activity or cellular localization (102). 
Aside from its function in the production of phosphatidylinositol-3-phosphates, PI3K 
also has serine kinase activity and the catalytic and regulatory subunits are able to 
interact with other proteins. There are three main classes of molecules regulated by 
phosphatidylinositol-3-phosphates: the AGe family of serine/threonine protein 
kinases, guanine nucleotide-exchange proteins of the Rho family of GTPases, and the 
TEe family of tyrosine kinases (102). One kinase of the AGe family is 
phosphoinositide-dependent kinase 1 (PDK1). Although the precise interaction 
remains to be determined 3' -phosphoinositides affect two serine/threonine kinases, 
PDK1 and Akt (also known as PKB) (114). PI3K has been confirmed to playa role in 
metabolic signalling, and in skeletal muscle cells it has been established that 
stimulation of the PI3K pathway by insulin is crucial for the insulin-stimulated 
glucose uptake. Inhibition of PI3K activity has been shown to completely abolish 
glucose uptake and GLUT4 translocation in skeletal muscle and adipose cells 
(15.1,55). 
1.5 Akt 
Akt is a serine/threonine kinase with three isoforms identified in mammals; 
Aktl, Akt2, and Akt3. Full activation of Akt requires phosphorylation of two of its 
residues, threonine residue (Thr308) and serine residue (Ser473). The mechanism of 
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this phosphorylation is not completely understood. It still remains unclear how the 
serine residue becomes phosphorylated, although the integrin-linked kinase (ILK) 
appears to be dependent on PI3K and is capable of phosphorylating the Ser473 site. It 
is known that the threonine residue is phosphorylated by PDK1 and this 
phosphorylation of Akt is thought to occur after polyphosphoinositide binding which 
increases Thr308 accessibility (112). It has been demonstrated that the Akt2 isoforrn 
is important in insulin-stimulated glucose uptake and GLUT4 translocation and it has 
been found to specifically associate with GLUT4 containing vesicles and to 
phosphorylate proteins associated with GLUT4 vesicle. The crucial downstream 
targets of Akt in glucose uptake remain to be identified (3,54,55). Substrates of Akt 
include the serine/threonine kinase GSKW, proapoptotic proteins BAD and caspase 
9, 6-phosphofructose-2-kinase, the forkhead family of transcription factors, and the 
Akt substrate 160kDa (AS160) (112,113). AS160 has been shown to mediate GLUT4 
trafficking in L6 GLUT4myc expressing myoblasts. When AS 160 is in its 
nonphosphorylated state it inhibits GLUT4 translocation to the plasma membrane, 
and phosphorylation of AS 160 by Akt leads to GLUT 4 translocation in skeletal 
muscle cells (113). 
Although it has been w.ell established that the activation of the IRS/PI3K1 Akt 
signalling pathway is essential for insulin-stimulated glucose uptake and GLUT4 
translocation, there is room to believe that other signalling molecules or pathways are 
required. So far no studies have been able to explain the specificity of the PI3K 
response to insulin. PI3K is activated by a variety ofhorrnones and growth factors but 
only activation of PI3K by some of these activators results in glucose uptake and 
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GLUT4 translocation (31,48.1,80,112,113). And while in muscle both insulin and 
PDGF stimulate activation of PI3K and Akt phosphorylation, only insulin induces 
Akt phosphorylation in adipocytes (112,113). Additionally, studies in adipocytes 
using a cell permeable analog of PI3,4,5P3 show that administration of the analog 
alone does not lead to glucose uptake while the co-administration of the analog with 
insulin into cells pre-treated with wortmannin, a very potent PI3K inhibitor, show 
enhanced glucose uptake. Further examination showed that the analog induced 
GLUT4 translocation but the transporters were not functional (112). This indicates 
that not only translocation but also activity of GLUT4 is important for the increase in 
glucose uptake. These experiments support the presence of a PI3K-independent 
pathway that is essential for glucose transport activation. As reviewd by Summers et 
al (112) other studies also demonstrate a lack of correlation between IRS-associated 
PI3K and insulin-stimulated glucose uptake and/or GLUT4 translocation, showing 
that although the insulin-stimulated IRS phosphorylation is required for some PI3K 
responses it is not required for GLUT4 translocation and that the association between 
IRS and PI3K may have little impact in glucose uptake even though PI3K is still 
required for GLUT4 translocation. 
N aringenin 9 
Skeletal Muscle 
Cell 
GLUI4 
,/ 
C-P-DK-D 
" 
o 
Figure 2: Key elements of the insulin signalling cascade leading to glucose 
uptake in skeletal muscle cells 
1.6 The CAP/Cbl Pathway 
o 
o 
o 
The CAP/Cbl pathway seems to be another pathway required for insulin-
stimulated glucose uptake. CAP belongs to a family of adaptor proteins that contain 
three SH3 domains and a sorbin homology (SoHo) domain. This protein associates 
with a Cbl molecule through its carboxyl-terminal SH3 domain. In this pathway the 
insulin receptor phosphorylates Cbl on tyrosine residues, which leads to the 
translocation of the Cbl-CAP complex to lipid raft domains in the plasma membrane. 
Once translocated the Cbl recruits the adaptor protein CrkII where CrkII forms a 
complex with the C3G protein. The movement of C3G, a guanyl nucleotide-
exchanger, to the lipid rafts allows it to associate with the G-rotein TClO and catalyze 
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the exchange of GTP for GDP. This in tum activates TelO which creates an 
additional signal for GLUT4 proteins (55,102). 
1.10 Other Mechanisms Mediating Glucose Uptake 
1.10.1 Exercise 
It has been established that physical exercise has many beneficial effects on 
physiological processes and in metabolic disorders including decreasing the risk of 
susceptible populations to developing insulin resistance and type 2 diabetes, and 
improving the lipid profile and lowering blood glucose in type 2 diabetic patients 
(28,51,86). Exercise and contraction lead to significant changes in skeletal muscle 
metabolism including increases in glycogen breakdown, glycolysis, glucose uptake, 
fatty acid oxidation, post-exercise insulin sensitivity, and leads to changes in gene 
expression (28,36). The mechanisms mediating the exercise-induced increase in 
glucose uptake have remained elusive. Evidence suggests that exercise stimulates 
glucose uptake in skeletal muscle is independent of the insulin signalling pathway. 
Acute exercise does not appear to stimulate the insulin signalling pathway, having no 
apparent effect on tyrosine phosphorylation of the insulin receptor or IRS-I, and does 
not increase PI3K activity. Furthermore the exercise-stimulated increase in glucose 
uptake is not impaired by inhibjtion of the insulin signalling pathway (83,101.1) 
On the other hand there is strong evidence implicating AMP-activated protein 
kinase (AMPK) in regulating the short-term and long-term adaptations of exercise in 
skeletal muscle (28,84). Exercise and muscle contraction activates AMPK in rodent 
and human skeletal muscle, liver, and adipose cells (33,51,86,124). For instance 
treadmill exercise in rat skeletal muscle, sciatic nerve-stimulated muscle contractions 
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in situ, contraction of isolated muscle in vitro, and moderate to high exercise in 
humans all show increased AMPK activity (28,84,86,124). Thus various experimental 
models (treadmill exercise in rats, nerve-stimulated muscle contraction in situ, 
contraction of isolated muscle, exercise in humans) consistently show that exercise 
and contraction stimulate AMPK activity in muscle (84,86). Although there is 
extensive evidence showing that AMPK stimulates glucose uptake in skeletal muscle 
its mechanism of action and the signaling pathway that it is part of remains to be 
determined (Figure 3). 
o o 
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Figure 3: Other mechanism of increasing glucose uptake. AMPK is a sensor of 
cellular energy status and is stimulated by rising AMP to A TP ratio due to A TP 
depletion. Therefore it is activated by metabolic stresses that either inhibit ATP 
production (e.g. hypoxia) or increase ATP consumption (exercise, muscle 
contraction). Some antidiabetic drugs including metformin and troglitazone are 
reported to mediate their action via activation of AMPK. 
1.10AMPK 
The genes that encode for AMPK are present in all eukaryotic cells for which 
genome sequences have been completed, from single-celled organisms such as 
budding yeast (Saccharomyces cerevisiae) to highly specialized mammals (35,37). In 
mammalian cells the AMPK system acts as a sensor of changes in cellular energy 
status, regulates numerous processes of cellular metabolism, integrates nutritional and 
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honnonal signals in the peripheral tissues and the hypothalamus, and mediates the 
effects of adipokines in regulating food intake, body weight and glucose and lipid 
homeostasis (13,34,51,56). 
1.10.1 Structure of AMPK 
In 1994 the AMPK molecule was purified and identified as a complex consisting 
of three subunits. These subunits include a catalytic a and regulatory ~ and y units. 
Mammals have two genes encoding a subunits (al and a2), two encoding ~ subunits 
WI and ~2), and three encoding y subunits (yl, y2, and y3). All isofonn combinations 
seem to be able to fonn an AMPK complex giving rise to at least 12 possible isofonn 
combinations with splice variants and alternative promoters adding to the number. 
The molecular weight of the a isofonns are ~63kDa, the ~ subunits are ~30kDa, and 
the y subunits are variable ranging from ~37-63kDa (13,28,118). The a subunit 
contains a serine/threonine kinase catalytic domain located at the N-tenninal half 
(13,35,). It also has several residues that can be phosphorylated (ThrI72, Thr258, and 
Ser485 (a 1)/491 (a 2)) and the phosphorylation by upstream kinases of the Thr172 
residue located on the activation loop of the kinase's catalytic domain is necessary for 
activation of AMPK. Site directed mutation of Thrl72 to alanine renders the kinase 
inactivity, and phosphorylatioJ.l of Thr172 mimics the activity of AMPK under all 
tested conditions (13,35). The C-tenninus of the a subunit contains a sequence 
required for fonnation of the complex with the other subunits and an inhibitory 
domain has been proposed with the C-tenninal half. Both the y and ~ domains are 
obligatory for full AMPK enzymatic activity (28,35). The ~ subunit contains a 
glycogen-binding domain, a C-tenninus necessary for complex fonnation with the a 
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and y subunits, and multiple phosphorylation sites although their corresponding 
upstream kinases and the effects of phosphorylation at these sites remains a point of 
science (13,35). The y subunits have variable N-terminal regions followed by four 
cystathionine-~-synthase (CBS) domains. These domains act in pairs, each pair 
forming a segment referred to as a Bateman domain. The Bateman domain forms a 
binding site for AMP. Naturally occurring point mutations in the Bateman domains 
suggest that an AMP molecule has to be bound to each of them in order for AMPK 
activation to occur (14,32,35,51). 
1.10.2 Cellular Distribution of AMPK Isoforms 
AMPK is expressed throughout most mammalian cells but the expression 
pattern of the isoform is tissue-specific. The aI, ~1, and yl isoform is the 
predominant form of AMPK expressed in most cell types. The a2, ~2, y2, and y3 
isoforms are also highly expressed, in skeletal and cardiac muscle cell, while a2 is 
also significantly expressed by liver cells (34). The differences in isoform 
combinations are known to vary some of the AMPK function and the type of a and y 
isoforms determine the degree of dependence that the molecule has on AMP for 
activation. Thus variations in AMPK isoforms allow for some tissue-specific AMPK 
functions. In addition to tissue:specific -expression of the different isoforms, there are 
also variations in the cellular localization of the isoforms with a large portion of 
AMPK with the a2 isoform being associated with the nucleus while those with al are 
mainly found in the cytoplasm (28,34). 
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1.10.3 Regulation of AMPK 
AMPK is a sensor of cellular energy status and is stimulated by rising AMP to 
A TP ratio due to ATP depletion. Therefore it is activated by metabolic stresses that 
either inhibit ATP production (heat shock, ischemia, hypoxia, hypoglycemia, 
metabolic inhibitors such as arsenate or oligomycin, glucose deprivation) or increase 
A TP consumption (exercise, muscle contraction) (34,37,56). It is now known that 
AMPK is also stimulated by signals that do not cause changes in the AMP to A TP 
ratio (e.g. hyperosmotic stress, metformin) (13). 
1.10.3.1 AMPK as an intracellular energy sensor and its regulation by 5'-AMP 
As its name implicates AMPK is activated by 5'-AMP. This occurs via three 
different mechanisms: allosteric activation of the phosphorylated molecule, 
phosphorylation of Thr 172 by upstream kinases and inhibition of dephosphorylation 
of Thr172 by protein phosphatases (35). This multiple mechanism of activation 
makes AMPK very sensitive to small changes in the AMP to A TP ratio. AMP is 
produced in several reactions but the majority is produced by the adenyl ate kinase 
reaction: 2ADP <-> ATP + AMP. Healthy cells at rest usually have a high ATP to 
ADP ratio making the direction of the above reaction favour production of ADP and 
resulting in low AMP levels. Conversely, cellular situations which result in a 
depletion of A TP, and therefore a low ATP to ADP ratio, will result in an increase in 
AMP levels. Decreases in ATP levels will drive an increase in AMP (35,37). 
Allosteric activation by AMP causes an up to 5-fold increase in activity while 
phosphorylation of the Thr172 residue by upstream kinases results in more than a 
100-fold increase in AMPK activity. Although allosteric activation alone renders 
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AMPK relatively inactive until phophorylated by upstream kinases, the 
phosphorylation process appears to be largely influenced by the binding of AMP to 
AMPK which causes AMPK to be a better substrate for phosphorylation. The effect 
of AMP on both phosphorylation and dephosphorylation of AMPK appears to be due 
to binding of the molecule to AMPK rather than the upstream kinase or phosphatase 
(51 ,118). As mentioned earlier each of the Bateman domains found on the gamma 
subunit bind one molecule of AMP or ATP in a mutually exclusive way (35,51). 
Consistent with this all three mechanisms of AMP on AMPK are antagonized by high 
concentration of A TP most likely due to competition between the molecules. In 
addition to interfering with AMP binding, ATP binding to the AMPK inhibits 
phosphorylation by upstream kinases and stimulates dephosphorylation by 
phosphatases. This emphasizes the importance of a rising AMP to A TP ratio as the 
stimulant for AMPK activation rather than simply a rise in AMP or decrease in A TP 
on their own (34,37,118). 
1.10.3.2 Upstream Kinases of AMPK 
Activation by LKBI 
LKB 1 exists as a complex with two other subunits, STE20-related adaptor 
protein (STRAD), and mouse .protein 25 (M025), and is required for activation of 
AMPK in response to stimuli that increase AMP or compounds that mimic AMP both 
in cell culture and skeletal muscle in vivo. STRAD, which is a pseudokinase, and 
M025, which stabilizes the association of LKB 1 and STRAD, are both required for 
catalytic activity. Localization of LKB 1 to the cytoplasm also appears to be 
dependent on the binding by M025 and STRAD (32,51,118). The LKB1 is 
Naringenin 17 
ubiquitously expressed and appears to be constitutively active. LKB 1 activity is not 
stimulated directly by either upstream stimuli of AMPK or by AMP. Instead AMP 
binding to AMPK causes AMPK to become a better substrate for LKB 1 and thus 
activate the LKBI-AMPK cascade (32,35,51,118). Before the determination that 
LKB 1 phosphorylates AMPK, LKB 1 had no identified physiological downstream 
target. Recently it has been shown that LKBI activates 11 AMPK-related kinases by 
phosphorylating a comparable residue to Thr172 in AMPK. This implies that the 
function of LKB 1 may be that of a master kinase which opens the possibility that 
some of its actions could be mediated by the AMPK-related kinases. However, the 
physiological role of these kinases as it relates to LKB1 is not know (32,51). 
Activation by CaMKKs 
AMPK can also be stimulated by AMP-independent mechanism which is 
demonstrated by that the phosphorylation of Thr172 by the ca2+/calmodulin-
dependent protein kinase kinases (CaMKKs) is not stimulated by increasing 
AMP:ATP ratio but instead by a rise in calcium (35). Although more work needs to 
be done to determine the tissue distribution of this pathway, CaMKKs appear to be 
mainly expressed in neural tissue and muscle-specific knockouts of LKB 1 suggest 
that the calcium-mediated pathway cannot have a significant contribution in skeletal 
muscle. However, contraction-induced glucose transport in skeletal muscle cells is 
believed to be in part mediated by increased cytosolic calcium levels and activation of 
the calcium/calmodulin-dependent protein kinase, and some studies in muscle suggest 
that a role for CaMKK in muscle (35,49,69). 
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1.10.4 AMPK Function in Metabolism 
Since AMPK is instrumental in maintaining energy balance at a cellular and 
whole body level it may be important in disorders of energy metabolism such as 
obesity, Type 2 diabetes, and metabolic syndrome. Consistent with this idea, AMPK 
activation causes many metabolic changes that would be beneficial in subjects with 
these conditions including increased glucose uptake and metabolism by muscle and 
other tissue, decreased glucose production by the liver, and decreased synthesis and 
increased oxidation of fatty acids (28,34,35,51). AMPK plays a role regulating energy 
intake, utilization, and storage by affecting the intake of food and metabolism. To do 
this it mediates the action of many molecules and pathways of skeletal muscle, heart, 
adipose tissue, liver, pancreatic ~ cells, and the brain which regulate glucose and lipid 
uptake, storage, and utilization (51). In general AMPK activation inhibits A TP 
consuming pathways, particularly biosynthetic pathways in order to conserve ATP, 
and turns on A TP generating pathways. This is achieved by its acute effects as a 
kinase resulting in phosphorylation of enzymes and by chronic effects on gene and 
protein expression (51). In transgenic animal models deletion of both a 1 and 2 
subunits results in a phenotype incompatible with life, deletion of only al does not 
present with any observable metabolic phenotype, and deletion of a2 results in a 
phenotype with mild insulin-resistance and an insulin-secretory defect. Consistent 
with a role of AMPK in the hypothalamus, feeding the a2 knockout mice with a high 
fat diet leads to weight gain and fat mass compared to controls (51). In view of its 
regulating role of energy metabolism AMPK has become a potential target for 
treatment of type 2 diabetes and insulin resistance. 
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1.10.4.1 The role of AMPK in Skeletal Muscle Glucose Transport 
There are many studies implicating AMPK in glucose uptake m skeletal 
muscle. The initially studies were done usmg 5-aminoimidazole-4-carboxamide 
ribose (AICAR). AICAR is a nucleoside that is taken up into cells and converted to 
an AMP analogue, AICA riboside monophosphate (ZMP), which mimics the effects 
of AMP on the AMPK system resulting in AMPK activation (35,84,107). Although 
AICAR is not specific to AMPK and so results of these studies need careful scrutiny, 
the studies were able to show that AICAR stimulates glucose uptake in skeletal 
muscle cells and that AMPK is indispensable for this stimulation (28,29,42,84). Due 
to the limitation of AICAR studies transgenic and knockout animal models have been 
important in furthering the understanding of the role of AMPK in skeletal muscle 
glucose uptake. In both, the whole body AMPKal and whole body AMPKa2 
knockout mice the contraction-stimulated glucose transport was shown to be normal 
but there was also a noted two to three-fold increase in a1 expression and a 2-fold 
increase in contraction-induced al activity that might have compensated for some a2 
functions and explain the observed normal glucose uptake (28,29). In transgenic mice 
expressing a dominant-negative AMPKa2 isoform in skeletal muscle AICAR and 
hypoxia-stimulated AMPK activity and glucose transport were completely abolished, 
while contraction-stimulated glucose transport was decreased by only 30-40% (29). 
This further provides evidence that AMPK activity is necessary for AICAR's effect 
on glucose transport, but shows that it is only partly involved in the contraction 
stimulated glucose transport. Recently two LKB 1 knockout models were generated: a 
muscle specific LKB 1 knockout mouse, and a LKB 1 mouse that has a 70-80% loss of 
Naringenin 20 
LKB 1 in all body tissues and complete ablation of LKB 1 in skeletal muscle. These 
mice showed partial inhibition of contraction-stimulated glucose transport which 
could not be explained by a decrease in force production during contraction. These 
results illustrate that LKB 1 is necessary to generate a full contraction-stimulated 
glucose uptake in skeletal muscle cells but that other signals are also required in 
regulating glucose transport via this stimulus (29). 
1.10.4.2 Downstream Targets of AMPK in Glucose Uptake 
The signaling pathway or direct target(s) of AMPK-mediated glucose uptake 
in skeletal muscle has not been elucidated. It has been shown however that in cell 
lines that only express GLUTI transporters (clone 9 cells, 3T3 Ll pre-adipocytes, and 
C2Cl2 myoblast) AMPK activation increases glucose transport but does not alter 
GLUTI content in the plasma membrane suggesting that AICAR may stimulate the 
intrinsic activity of existing plasma membrane GLUTI transporters (28,29,84). In 
incubated papillary muscle cardiomyocytes and perfused rat hindlimb muscles 
AICAR-stimulated glucose uptake leads to increased GLUT4 translocation, and H-
:2Kb cells overexpressing constitutively active AMPK show an increase in GLUTI 
and GLUT4 translocation. Based on these studies it is likely that AMPK activity 
increases glucose uptake in s~eletal muscle cells by mediating glucose transporter 
translocation (84). The downstream molecules involved in glucose transport and 
glucose transporter translocation by AMPK have not been clearly identified but there 
has been extensive research and some suggestion have emerged including Akt 
substrate 160 kDa (AS 160), p38, and the sequential activation of the extracellular 
signal-regulated kinase (ERK), proline-rich tyrosine kinase-2 (PYK-2), phospholipase 
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D (PLD) and by atypical protein kinase C (aPKC) isoforms (29). The strongest 
evidence implicates AS 160. There are some similarities between the AMPK and Akt 
substrate motifs and it has been shown that both molecules phosphorylate 6-
phospofructo-2-kinase/fructo-2,6-bisphosphatase on Ser466. These facts suggest the 
possibility that AS 160 may also be a shared substrate (29,113). In a study with 
AMPKu2-inactve transgenic mIce it was shown that AICAR-stimulated 
phosphorylation of AS 160 was completely inhibited (29). Recently Thong et al 
provided evidence that AS160 may be the point of convergence mediating GLUT4 
trafficking by various signals including Akt, PKC, and AMPK (113). 
AMPK has also been implicated in regulating some effects of insulin and 
consistent with this, AMPKu2 null mice have impaired insulin sensitivity (13 ,35). 
The mTORlS6 kinase 1 (S6Kl) pathway is implicated in affecting insulin sensitivity. 
Activation of the mTORlS6K pathway results in inhibition of insulin signaling by 
affecting IRS and PI3K, which prevents the normal activation of the pathway by 
insulin and may lead to development of insulin resistance (51). Specifically, S6Kl 
phosphorylates the IRS proteins on serine residues, which prevents IRS tyrosine 
phosphorylation, and S6Kl decreases IRS protein levels by affecting its transcription 
and protein degradation. Micy with an inactive S6Kl are protected against the 
development of insulin resistance. The pathway regulating S6Kl activity includes 
includes the tumor suppressor products Tuberous Sclerosis Comples (TSC) proteins 1 
and 2. TSC proteins regulate the activity of mTOR by increasing Rheb-GDP levels, 
which reduce both mTOR and S6Kl activation (51). S6K1 is inhibited by being 
phosphorylated on Thr389 and AMPK has been shown to cause such 
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phosphorylation. Furthermore the signaling pathways of both AMPK and PI3K1Akt 
regulate TSC. Whereas the PI3K1 Akt pathway functions to prevents TSC activity 
leading to the activation of the mTOR pathway, AMPK phosphorylates and activates 
TSC leading to inhibition of mTOR. Another mechanism by which AMPK may 
blocks mTOR is by directly phosphorylating it (51). There is also evidence 
suggesting that AMPK may interact with molecules in the insulin signaling pathway. 
In cell-free assays AMPK phosphorylates IRS-Ion Ser789, an effect also observed in 
C2C12 myotubes with AICAR-induced AMPK activation, and in myotubes the 
phosphorylation is also associated with increased binding of PI3K to IRS-l 
(37,84,108). 
1.11 Diabetes Mellitus and Insulin Resistance 
Diabetes mellitus is a chronic metabolic disease and the number of people 
afflicted by it has been greatly increasing over the past 20 years and continues to 
increase due largely to population growth, aging, urbanization, and increasing 
prevalence of obesity and physical inactivity (73,98). The worldwide prevalence of 
diabetes for all age groups in 2000 was estimated to be 2.8% and is expected to rise to 
4.4% by 2030. The estimated number of people ~ 20 years of age with diabetes in 
2000 was ~ 171 million. Assuming that the prevalence of obesity remains the same 
this number is expected to more than double by 2030 to 366 million (98). In Canada 
1.4 million people have been estimated to have diabetes and this number is expected 
to increase to 2.4 million in 2016. This would indicate a 72% increase in the number 
of cases compared to an estimated population increase of 12%. This disease has a 
great economic burden in Canada with 2000 cost estimates being 4.66 billion and 
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with a projected increased costs of 8. 14billion by 2016 (90). In Ontario between 1995 
and 2005 the prevalence of diabetes has increased from 4.9% to 8.9%. Notably, 
although in both, the 1995 and 2005 estimates, the age adjusted prevalence is higher 
in the older age groups, the prevalence of diabetes among the younger age group has 
increased by 31 % more than in the older age group between the ten years (73). 
Diabetes is a condition in which the body is unable to adequately produce 
and/or use insulin. Insulin is critical in the regulation of glucose and fat metabolism 
as it has numerous metabolic functions in various tissues including stimulating 
glucose uptake into skeletal muscle and adipose tissue, stimulating lipid synthesis in 
adipose cells and liver, inhibition of glucose production and release from the liver, 
and inhibition of the release of fatty acids from triglycerides in adipose and muscle 
(5,63,99). As such, proper production and function of insulin plays an important role 
in controlling the switching between energy fuel utilization in order to meet the 
body's challenge of continuously supplying adequate energy to all of its cells in the 
face of irregular supply and ever-changing demand. Under normal conditions insulin 
promotes glucose utilization for energy hy the body while the lack of insulin leads to 
fat utilization and restricts glucose utilization to those tissues that normally can only 
utilize glucose, such as the brajn. This regulation maintains blood glucose levels in a 
narrow range in the unfed state. A principle mechanism controlling insulin release 
into the blood and thus this control is blood glucose concentrations: high blood 
glucose stimulating insulin secretion and low concentrations inhibiting insulin 
secretion. In diabetes mellitus blood glucose concentrations are unable to stimulate 
proper metabolic regulation by insulin and fail to maintain the normal range of blood 
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glucose levels, resulting in an abnormal metabolism of glucose and fat in various 
tissues (5,63,99,102,123). The deregulation of metabolism may lead to chronic 
complications such as retinopathy and blindness, neuropathy, nephropathy, 
amputations, and accelerated atherosclerosis (82,83 ,110). Based on Health Canada 
classification (43) patients are diagnosed with diabetes if they meet one of three 
criteria: 
1. They exhibit symptoms of diabetes such as fatigue, excessive thirst, excessive 
urination and unexplained weight loss, and have a casual plasma glucose level 
of 2: 11.1 mmol/L 
2. They exhibit a fasting plasma glucose test of2: 7.0 mmol/L 
3. They exhibit a plasma glucose level in the 2 hour sample of the oral glucose 
tolerance test 2: 11.lmmol/L. 
The underlying pathophysiology of diabetes is diverse and the disease occurs 
in three forms: type 1, type 2, and gestational diabetes (43). Gestational diabetes 
occurs in some women during pregnancy and usually is relieved after giving birth, 
although this condition is associated with an increa'sed risk for developing diabetes 
later in life (43). Type 1 diabetes, also known as insulin-dependent diabetes mellitus, 
is characterized by autoimmune destruction of the pancreatic p cells resulting in 
insufficient or complete lack of insulin secretion (110,123). The prognosis for 
subjects with this form of diabetes significantly improved after the discovery and 
purification of insulin between 1921-1922 by the efforts and contributions of 
Canadian researchers Frederick G. Banting, Charles H. Best, John J.R. Macleod, and 
James B. Collip at the University of Toronto (100). Daily injections of insulin at 
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appropriate times in these subjects helps maintain proper blood glucose levels and 
energy metabolism and delay the development of diabetes-related complications. 
Type 2 diabetes is the most common form of diabetes accounting for ~90% of cases 
(110). In type 2 diabetes the abnormal fat and glucose metabolism is usually due in 
part to resistance of skeletal muscle, liver, and fat to insulin action, and is highly 
correlated with obesity. There is an increase in glucose production and output by the 
liver and impaired disposal of glucose via insulin-stimulated glucose transport. At 
first the ~ cells compensate for insulin resistance and maintain relatively normal 
blood glucose levels by secreting more insulin. However, in the natural history of the 
disease there is a gradual progressive ~ cell failure to secret enough insulin to 
compensate for peripheral insulin resistance in the later stages of the disease (77,83) 
Both environmental and genetic factors are attributed to the development of 
type 2 diabetes and although the primary defect is unknown, insulin resistance in 
skeletal muscle has been established as an early defect in the pathogenesis of type 2 
diabetes. Other factors such as hyperglycaemia, hyperinsulinemia, and other 
metabolic irregularities may further diminish insulin action and contribute to the 
development of insulin resistance (63,123). Despite it being suggested that type 2 
diabetes begins with skeletal muscle insulin resistance studies with transgenic tissue-
specific knockout mice show that skeletal muscle insulin resistance may not on its 
own lead to the development of the disease (5,123). Saltiel et al (102) suggests a 
unifying hypothesis for the development of type 2 diabetes in which "insulin 
resistance in classic target tissues (liver, muscle, fat) coupled with insulin resistance 
in ~-cells, brain and other tissues, combine to produce the pathophysiology of type 2 
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diabetes". In recent years it has become recognized that in the pathophysiology of 
type 2 diabetes ~-cells failure occurs earlier than previously suspected, and to involve 
problems with skeletal muscle, adipose, liver, gastrointestinal track, a-cells of the 
pancreas, kidney, and brain (19.1). 
Insulin resistance refers to a reduced responsiveness of tissues to circulating 
concentrations of insulin and is a consistent feature of type 2 diabetes. This however 
underscores the heterogeneity of the insulin resistance phenotype, which may vary 
depending on which tissues are affected and which insulin pathways within those 
tissues are defective and to what degree (5). At a molecular level insulin resistance 
has been associated with several defects in the insulin signalling pathway including 
decreases in receptor concentration and kinase activity, the concentration and 
phosphorylation of IRS-I and -2 proteins, PI3K activity, and glucose transporter 
translocation (l02). Particularly insulin resistance in the skeletal muscle of obese and 
type 2 diabetic patients is associated with decreases in insulin receptor tyrosine kinase 
activity, decreased IRS-I-associated tyrosine phosphorylation and insulin-stimulated 
PI3K activation. Adipose tissue of obese individuals show a decrease in basal and 
insulin-stimulated 2-deoxyglucose uptake, a decrease in the number of insulin 
receptors, and a decrease in .insulin receptor tyrosine kinase activity and IRS-l 
associated PI3K activity. In the liver of obese individuals there is no significant 
change in the number of insulin receptors, insulin receptor kinase activity, or in 
insulin's ability to inhibit glycogenolysis (5). 
Presently there is no cure for diabetes mellitus as is true for many of the major 
chronic diseases inflicting large segments of the world population. There is a 
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multifactorial theory of current major diseases but we have not yet a clear paradigm 
shift in our understanding of chronic diseases such as diabetes mellitus although 
major advancements have been made. This means that the focus for the diabetic 
patient is life-long treatment regiments aimed at mimicking normal metabolic control 
and delaying associated complications, and prevention strategies for the general 
population to reduce the risk for development of the disease. For the type 2 diabetic 
this means adapting strategies for managing the condition and reducing the risk of 
complications such as healthy diets, weight management, regular physical activity, 
and/or using oral medications. Currently there are a variety of different classes of oral 
medications available for treatment of type 2 diabetes that differ in their targets and 
mechanism of action. These include drugs that stimulate insulin release from the ~ 
cells (sulfonylureas, meglitinides); inhibit glucose absorption by the gut (a-
glucosidase inhibitors); reduce hepatic glucose output through inhibition of 
gluconeogenesis and increase peripheral glucose transport (metformin); reduce 
insulin resistance at target tissues (thiazolidinediones or glitazones) (77,82). Given 
that the current strategy for therapy is management, the complexity and variety of the 
possible defects, and that as a result the current drugs have limited efficacy in certain 
patients due to their specific mechanisms, it is important to study novel compounds 
that may bypass insulin resistance by having an insulin-like effect by stimulating 
specific insulin signalling pathways or other pathways with similar effects, or by 
increasing insulin sensitivity, thus possibly leading to improved treatment options for 
type 2 diabetes. The study of such novel compounds and their mechanism(s) of action 
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also have indirect benefits in that they may lead to further elucidation of signalling 
pathways involved in metabolism, their cross talk, and unifying factors. 
1.12 Polyphenols 
Epidemiological studies suggest that a diet high in fruits and vegetables is 
protective against chronic diseases such as cardiovascular disease and cancer but the 
role played by individual components of these foods in this protection and to what 
extent they account for the decreased risk of disease is difficult to determine (24). 
Polyphenols have increasingly gained attention from the scientific community for 
their potential health benefits and as therapeutics against several chronic diseases. 
The main reason for the interest in polyphenols is due to recognition of them as the 
most abundant antioxidants of our diet and their abundant distribution in food and 
beverages of plant origin such as fruits, vegetables, cereals, legumes, chocolate, tea, 
and wine. The distribution of specific polyphenols in food varies with some being 
highly ubiquitous (e.g. quercetin) while others being specific to certain foods (e.g. 
naringenin in citrus fruit) (19,75). Apart from being constituents of a regular diet 
polyphenols are emerging as potential active components of certain traditional folk 
remedies (72,75). Polyphenols have been reported to have antioxidant properties and 
may protect against dise<;lses including cancer, cardiovascular disease, 
neurodegenerative diseases, and diabetes. Whether the beneficial health effects are 
due to antioxidant activity is not clear as some studies have shown pro-oxidant effects 
as well (19,31.1). Increasingly it is becoming known that in addition to their 
antioxidant properties, polyphenols possess a variety of other specific biological 
effects, such as regulation of enzymes, and may prevent diseases by mechanisms that 
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are independent of their antioxidant effects. The most extensively studied po1ypheno1 
is the stilbene resveratro1 (Figure 4) which has been reported to have anticancer, anti-
cardiovascular disease, and anti-diabetic properties. Resveratro1 is an activator of the 
protein deacety1ases called sirtuins. Mainly studies indicate that in mammalian tissue 
SIRTl, one of the members of sirtuins, may be involved in the biological effects of 
resveratro1 (19,46, 47, 65,106). 
With over 8000 po1yphenolic structures having been identified po1ypheno1s 
are one of the most widely distributed groups of compounds in plants (101). They are 
produced as secondary metabolites in plants and are involved in plant growth and 
reproduction, resistance to pathogens, protection from ultraviolet light, pigmentation, 
and flavor (75,101). Despite the name, polypheno1s have the common feature of an 
aromatic ring bearing at least one hydroxyl group although commonly they have 
several hydroxyl groups on aromatic rings. They can be divided into several 
different classes according to the number of phenol rings they contain and the 
structural elements binding the rings together. The main classes of po1ypheno1s are 
phenolic acids, stilbenes, flavonoids, lignans, and phenolic alcohols (Figure 4) 
(19,75). In addition to their diversity in chemical structure they can also exist as 
either bound to various sugars (glycosilated) or unbound (ag1ycons) (75). 
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Figure 4: The different classes ofpolyphenols. Taken from ref 19. 
1.12.1 Flavonoids 
Flavonoids are the largest class of polyphenols, with over 5000 flavonoids 
being identified, and are potent antioxidants in vitro (101). They share the common 
structure of 2 aromatic rings that are joined by a linear 3 carbon chain (C6-C3-C6) 
that forms an oxygenated heterocycle, and can be divided into 6 subclasses depending 
N aringenin 31 
on the type of heterocycle involved: flavonols, flavones, isoflavones, flavanones, 
anthocyanidins, and flavanols (Figure 5) (75). Naringenin, the focus of the present 
work, belongs to the flavanone subclass of flavonoids, which are characterized by a 
saturated 3-carbon chain of the heterocycle and an oxygen atom at carbon 4 (Figure 
5) (19). In plants flavonoids are usually present as glycosides and the flavanone 
subclass usually exists in foods bound to either a neohesperidose or a rutinose (75). 
High concentrations of flavanones in the human diet are only present in citrus fruit 
although they are also found in tomatoes and some aromatic plants such as mint. The 
dietary intake of flavanones are quite high in individuals consuming citrus fruit 
regularly and the glycoside forms of these compounds are present in high 
concentrations in many commonly ingested citrus fruits and juices. The main 
representatives of flavanones are naringenin, hesperetin, and eriodictyol, which are 
found in highest concentrations in grapefruits, oranges, and lemons, respectively 
(19,75,101). 
Figure 5: 
The different 
subclasses of 
flavonoids. Taken 
from ref 19. 
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1.12.2 Naringenin 
1.12.2.1 Naringenin Food Sources and Bioavailability 
It should be noted that several factors might influence dietary intake and 
bioavailability of flavonoids, which may also be true for naringenin. For one plant 
production of flavonoids is influenced by many factors including light, plant genetics, 
environmental conditions, germination, degree of ripeness, processing and storage, 
and species variety (101). Also whether the flavonoid is formed glycosilated or not, 
and its dietary source may affect bioavailability (101). The main food sources of 
naringenin are grapefruits, oranges, and tomatoes, with grapefruits by far containing 
the highest concentrations. Naringenin from citrus fruit is principally present in 
glycosilated forms: in oranges the main naringenin glycoside is narirutin (naringenin-
7-rutinoside) while in grapefruit narirutin is present to a lesser extent (20%) and the 
main form is naringin (naringenin-7 -neohesperidoside) (70%). In tomatoes 
(Lycopersicum esculentum) naringenin is one of the most abundant polyphenols, and 
is present in the skin as aglycon (12,22,24). 
There have been limited studies ascertaining the dietary intake of naringenin 
and given the before mentioned factors that influence food content of polyphenols 
and bioavailability it is difficult to extrapolate results to other populations. 
Furthermore it should be kept in mind that a considerable inter-individual variation in 
naringenin uptake and metabolism has been reported in the results. In Finland the 
average intake of naringenin is estimated to be 8.3 mg/day while in another study the 
daily intake in a high-vegetable/fruit diet was 29 mg with a mean plasma naringenin 
concentration of 112.9 nmollL (a range of 40-2120 nmollL in 22% of the individuals 
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taking naringenin) (23,24). Naringenin content of grapefruit juice has been reported 
to be 1283 , . nlloI/L with a resulting plasma concentration range of 0.7-14.8 I1mollL; in 
orange juice content of naringenin has been reported to be 141 jlillol/L with plasma 
concentrations of 0.1-1.2 I1mol/L; and naringenin concentration of a tomato has been 
reported to range from 0.8-4.2 mg/l00g in whole red tomato, and after ingestion of a 
tomato paste test meal containing 3.81 mg of naringenin the peak plasma 
concentration resulted in 0.12 I1moi/L (12,22,23) Taken together in all the a~ove 
mentioned studies the plasma concentration of naringenin in individuals consuming 
naringenin-rich foods is in the 11M range (Table 1). 
Table 1: Plasma Concentration ofNaringenin in Humans after ingestion from food 
sources. 
Food Source Amount ofNaringenin Plasma Concentration Referen 
ingested 
ce 
Orange Juice, half 29mg 112.9 nmoliL a 23 
orange, half mandarin 
Orange Juice 85).lmol 0.1-1.2).lmoI/Lb 22 
23 mg 175 ).lg/L 
Grapefruit Juice 731 ).lmol 0.7-14.8 ).lmol/Lc 22 
199mg 1628 ).lg/L 
Tomato Paste 3.81 rug in tomato paste 0.12 ).lmol/Lct 12 
a - mean. Large number of subjects had values below detectable via method. 
b,c - values are range and mean peak plasma concentrations, respectively. 
d - mean peak plasma concentration. 
In general polyphenols follow a common pathway of metabolism. Both the 
aglycones and glycosides can be absorbed in the body. The aglycones can be 
absorbed from the small intestine and pass passively into the blood stream from the 
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gut but the glycosides are more hydrophilic and may require transporter proteins 
and/or to be hydrolyzed by intestinal enzymes or colonic microflora in order to be 
absorbed (75,94). Peak naringenin concentration are reported to be reached at 5.5h 
and 4.8h for grapefruit juice and orange juice, respectively, which according to the 
researcher suggests that naringenin from these juices is absorbed from the distal parts 
of the small intestine or the colon (22). During absorption polyphenols are conjugated 
in the small intestine and the liver, which includes methylation, sulfation, and 
glucuronidation, and the resulting conjugates are largely bound to albumin in the 
circulation. The effect of albumin binding on the biological activity of polyphenols is 
however unclear (75). In the study examining the bioavailability of naringenin from 
tomato paste only conjugated naringenin was detectable in plasma samples suggesting 
that naringenin is extensively metabolized in the liver from where it leaves to the 
general circulation in the conjugated form (12). 
The elimination of polyphenols mainly occurs in urine and bile, and via the 
biliary route they may be again reabsorbed (75). Compared to other flavonoids, 
flavanones have short half-lives although the results of urinary excretion have varied 
in different studies. The urinary recovery of naringenin has been reported as 5-59%, 
5%, 14-15%, and 1-6% in diff~rent studies (22). Erlund et al (23) found that 63% of 
total urinary excretion of naringenin was excreted in a 4-8h fraction from grapefruit 
juice and 83% from orange juice (23). Fuhr et al (reviewed in 22) found that the half 
life for naringenin and naringenin glucosides after ingestion of grapefruit juice was 
2.9 and 2.6 h, respectively, while in a study by Erlund et al (23) the half life was 1.3-
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2.2 h. The amount of excreted of naringenin appears to be dependent on the serving 
sizes ingested (22,23). 
1.12.2.2 Biological Effects 
Intake of citrus has been proposed to have several beneficial properties 
including anti carcinogenic, antiviral, and anti-inflammatory and epidemiological 
studies have shown that the consumption of citrus fruits or juices, which contain high 
amounts of naringenin, have a protective effect on the risk of ischemic stroke and 
different cancers (23,24). Furthermore epidemiological studies are reported to show 
that intake of tomatoes and tomato-based products have an inverse correlation with 
risk of certain cancers (12). There are however limited studies on the impact of 
specific flavonoid intake on disease incidence partly due to the large variety of the 
compounds in foods and the complexity of collecting accurate data on food intake 
and on intake of specific flavonoids. This helps to explain the inconclusiveness of 
epidemiological studies on the effects of specific flavonoids on health with some 
studies supporting reduced risks of chronic diseases such as cancer and 
cardiovascular disease with higher intake, some reporting no effect, and others still a 
potentially negative effect. Most epidemiological studies have focused on flavones 
and flavonols intake but not m"any have examined the impact of flavonones (59). In 
one study which measured the intake of a variety of flavonoids including naringenin 
it was observed that a high intake of certain flavonoids was associated with reduced 
risk of mortality from ischemic heart disease, incidence of cerebrovascular disease, 
incidence of specific cancers and asthma, and a trend towards a decreased risk for 
type 2 diabetes. Naringenin intake was associated with a reduced risk of 
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cerebrovascular disease (59). The study was limited by small number of cases of 
certain diseases and in that intake was measured by questionnaires and no biomarkers 
of the different flavonoids were measured making the data subject to recall bias. 
However because naringenin is found in foods that are a main ingredient (i.e. 
grapefruit vs. onions which would be considered a hidden ingredient as it is often 
added to dishes and eaten as part of a mixture) the food intake is expected to have 
been fairly accurately measured (59). Although the amount of flavonoids in sample 
foods was measured in the study the absorption and bioavailability of the compounds 
was not (59). 
Studies specifically looking at the effects of nanngemn have reported 
antioxidant, anti-proliferative, and anticancer properties. In vitro studies usmg 
different cell lines have identified naringenin as an effective antioxidant and in vivo 
naringenin partially protects against oxytetracycline-induced oxidative stress in rat 
liver (1,22,92). However, in the weanling rat strain exposed to oxidative stress diets 
naringenin did not exhibit antioxidant effects (1). Other biological activities 
attributable to naringenin include anti-inflammatory actions and effects on sex 
hormone metabolism (22). Also naringenin inhibits the cytochrome P450 enzyme and 
therefore may increase the con<;;entration of certain drugs that are metabolized by this 
enzyme (22,24). Other effects of naringenin may be on lipid and glucose metabolism 
(discussed below). 
1.12.2.3 Effects of Naringenin on Metabolism: Animal Studies 
A variety of herbal medical preparations traditionally used for the treatment of 
diabetes exist and their extracts have been tested and shown to possess antidiabetic 
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properties. Of these extracts several have been identified to contain flavonoids but 
only in some cases have the specific flavonoid composition been elucidated. 
Cochlospermum vitffolium (Willd.) Sprengel, also known "panicua", is a tree found in 
Mexican which bark is used in traditional medicine for the treatment of hypertension, 
type II diabetes, and hepatitis. Not until recently have there been reports of isolated 
active compounds from this preparation with vasorelaxant, hypoglycaemic and 
hepatoprotective activities (103). A study by Sanchez-Salgado et al (103) aimed to 
confirm the antidiabetic and antihypertensive properties of this preparation. They 
tested hexane, dichloromethane, and methanol extracts from the preparation for their 
vasorelaxant, hypoglycaemic, and hepatoprotective activities in male Wistar rats. 
Chromatography fractionation of the methanol extract isolated naringenin. The study 
found that the methanol extract and naringenin exerted vasorelaxant activity and the 
methanol extract showed a hypoglycaemic effect but which did not reach statistical 
significance. Unfortunately the researchers did not specifically test the 
hypoglycaemic potential of naringenin in this study (103). 
Studies in rodents have shown that naringenin possesses hypocholesterolemic 
and hypoglycaemic effects, and improves hyperlipidemia and atherosclerosis. In a 
study examining the hypoglycaemic and hypolipemic properties of naringenin 
isolated from sterns of Prunus davidiana, a Korean folk medicine for neuritis and 
rheumatism, in streptozotocin-induced diabetic rats the researchers found that 
intraperitoneal administration of naringenin (10 mg/kg body weight) significantly 
decreased plasma glucose concentrations by 10%, decreased triglycerides levels by 
61 %, and decreased total cholesterol levels by 25% (17). In another study the same 
.....-
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researchers examined the effects of naringenin on serum parameters in high-fat fed 
rats (18). In the study naringenin was shown to exhibit a significant 
hypocholesterolemic effect with the naringenin treated group (20 mg/kg B.W.) 
resulting in a significant 9% decrease in total cholesterol. A study by Santos et al 
(104) examined the effect of naringenin on lipid metabolism in hyperlipidimic rats 
and found that naringenin significantly reduced cholesterol levels and triacylglycerol 
levels. 
A study by Lee et al (70) provides some elucidation into the mechanism of the 
cholesterol lowering effect of naringenin in which high-cholesterol fed rats where 
supplemented with or without naringenin. The study found that naringenin did not 
. alter plasma triglyceride levels but significantly reduced plasma cholesterol levels and 
hepatic cholesterol content. The effects on two key enzymes, acyl-CoA:cholesterol 
acyltransferase (A CAT) and 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA 
reductase), involved in cholesterol metabolism were also examined. ACA T is 
involved in the formation of cholesteryl esters, cholesterol absorption from the diet, 
hepatic secretion of very low-density lipoprotein (VLDL)-cholesterol, and in the 
development of foam cells in atherosclerosis (70). HMG-CoA reductase is a rate-
limiting enzyme of cholesterol formation (68). This study found that naringenin 
supplementation reduced the activity of both of these enzymes (70). In another study 
the anti-atherogenic effects of naringin and naringenin in high cholesterol-fed rabbits 
was examined (68). The animals that were fed a 1 % cholesterol diet supplemented 
with naringin or naringenin showed reduced activity of hepatic ACA T by 5% and 
15% respectively, a reduction of the aortic fatty streak areas by 19.2% and 18.1 % 
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respectively, and reduced expreSSIOn levels of vascular cell adhesion molecule-1 
(VCAM-1) and monocyte chemotactic protein-I (MCP-I). Adhesion ofmonocytes to 
the endothelium is an early step in the development of atherosclerosis and VCAM-1 
is suggested to be involved in the recruitment of monocytes in this condition. MCP-1, 
in addition to recruiting monocyte, also promotes the release of lipids and lysosomal 
enzymes into the extracellular space which leads to the progression of atherosclerosis 
(68). 
The hypoglycemic effects of naringenin in vivo have been less studied. A 
study by Li et al (71) examined the effects of naringenin on intestine and renal brush 
border membrane vesicles (BBMV) of normal rabbits (intestine BBMV only) and 
normal and STZ diabetic rats. The study found that glucose uptake activity in the 
intestine BBMV of rabbits was moderately inhibited by naringenin. However glucose 
uptake in intestine and renal BBMV of STZ diabetic rats was significantly higher 
than in normal rats and naringenin (500 11M) normalized this uptake to levels similar 
to control rats. Naringenin decreased glucose uptake in both diabetic and normal rats 
by ~80% in intestina~ BBMV and by ~60 in the renal BBMV (71). 
1.12.2.4 Effects of Naringenin on Metabolism: Cell Culture Studies 
There are limited studies examining the metabolic effects of naringenin in cell 
culture. There have been a few studies examining the mechanism of the 
hypolipidemic effects of naringenin in hepatocytes HepG2, and naringenin has been 
shown to inhibit apolipoprotein B (apoB) secretion in these cells, an effect also 
observed by insulin (7,8,9). Hepatic overproduction of apoB-containing lipoproteins 
(apo-Lp) is associated with a number of hyperlipoproteinemias. ApoB provides the 
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structural framework for the formation of very low density lipoproteins (VLDL) (7). 
Prior to their secretion, apoB associates with lipids in the endoplasmic reticulum 
(ER), initially acquiring small amounts of phospholipids, triglycerides (TG), and 
cholesteryl ester (CE), and as the protein is further translated and translocated into the 
rough ER more lipids are aquired (7). The synthesis of CE and TG is performed by 
ACAT and diacylglycerol acyltransferase (DGA T), respectively, and the microsomal 
triglyceride transfer protein (MTP) transfers the synthesized lipids to apoB. MTP is 
necessary for lipoprotein formation and secretion (7). Research by Borradaile et al 
has shown that the naringenin-stimulated reduction in apoB secretion is associated 
with reduced ACAT and MTP activities and reduced expression of MTP and ACA T2 
(the form of ACAT expressed exclusively in liver and intestine). It has also been 
shown that naringenin inhibited accumulation of both TG and CE in the microsomal 
lumen suggesting that as a consequence the availability of lipids for the assembly of 
hepatic apoB-Lp is inhibited. Notably newly synthesized CE within microsomal 
lumen, secondary to ACAT activity, does not seem to be the means of inhibiting 
apoB secretion. Naringenin was also shown" to increase intracellular degradation of 
apoB. Ultimately these studies lead to the determination that naringenin inhibits the 
apoB-Lp assembly and subsequent secretion of apoB-containing lipoproteins by 
limiting the accumulation ofTG in the ER via MTP inhibition (7,8). 
Insulin is known to inhibit ApoB secretion in hepatocytes by activating PI3K 
which leads to increased sterol regulatory element-binding protein (SREBP)-l and 
LDL receptor expression. LDLr activity can regulate net apoB secretion by directing 
uptake of the newly secreted apoB-Lp and leading nascent apoB-Lp to degradation 
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(9). In further elucidating the inhibitory effect of naringenin on apoB secretion 
Borrandaile et al (9) examined the effect of naringenin on expression and activity of 
SREBP-l and LDLr. The study found that naringenin has an insulin-like effect to 
stimulate PI3K and causes a PI3K-dependent increase in cytosolic and nuclear 
SREBP-l and LDLr expression. Both naringenin and insulin were also shown to 
decrease insulin receptor substrate IRS-2 levels although, unlike insulin, naringenin 
did not stimulate tyrosine phosphorylation of IRS-l (9). 
There are no reported studies of the effects of naringenin on glucose uptake in 
skeletal muscle cells in vitro, but there are a few in other cell types including 
adipocytes, monocytes, and breast cancer cells. Based on a previous report that the 
isoflavone genistein worked as an inhibitor of glucose transport but that there 
remained conflicting reports as to the inhibitor effects of flavonoids on glucose 
transport, Park (94) examined a variety of flavonoids with respect to their glucose 
transport blocking potential in U937 monocytes. The study found that several of the 
flavonoids blocked glucose uptake with various efficacy the most potent of which, 
fisetin, blocking ~half of the glucose uptake with 8uM. Naringenin exhibited a 
relatively weak inhibitory effect on glucose uptake with a 50% reduction in basal 
glucose uptake requiring approximately 50 JlM naringenin. Harmon et al (40) 
examined the effect of naringenin on glucose uptake in 3T3-LI adipocytes and the 
study found that naringenin inhibited insulin-mediated glucose transport is a dose-
dependent manner with 100 JlM naringenin inhibiting glucose uptake by ~85%. In the 
study naringenin did not affect the phosphorylation of the insulin receptor, IRS-
proteins, or PI3K, but inhibited the phosphorylation of Akt (40). In an in vitro PI3K 
--
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activity assay, naringenin blocked production of PIP3 by PI3K, an effect similar to 
that of wortmannin. In the same study 6uM naringenin, a physiologically obtainable 
concentration, was shown to inhibit insulin-stimulated glucose uptake by 20%. In 
study examining the effects of naringenin on glucose uptake in M CF -7 breast cancer 
cells naringenin treatment was found to inhibit insulin-mediated glucose uptake in 
proliferating and growth arrested cells (39). Breast cancer cells overexpress GLUTl 
and often also express the GLUT4 transporters and experienced increased glucose 
uptake in response to insulin (39). In this study naringenin inhibited the 
phosphorylation of Akt of MCF -7 cells and phosphorylation of MAPK. The authors 
indicate that in this cell line the MAPK pathway seems to play an important role in 
insulin-stimulated glucose uptake by showing that inhibition of the pathway with a 
MAPK kinase inhibitor, PD98059, decreased the insulin-stimulated glucose uptake 
by ~60%. In the MCF-7 cells naringenin was shown to inhibit cell proliferation, a 
result which was also observed when glucose concentration was decreased in the 
growth media. Lastly the study showed that a physiologically attainable dose of lO 
~M naringenin decreased insulin-mediated glucose uptake by 25% and cell 
proliferation (39). 
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CHAPTER 2: Rationale and Hypothesis 
The role of insulin in regulating metabolism is complex as it has diverse 
actions and affects different types of tissues. The underlying cause of dysfunction that 
occurs in some people which leads them to develop insulin resistance, and why 
insulin resistance manifests itself in different ways is not fully understood. Therefore 
treatment for insulin resistance at present is focused on management rather than cure. 
Management is difficult given the diverse and coordinated actions of insulin, and 
present oral treatments are limited in their efficacy due to their specific targets and 
mechanism(s). The study of the effects of novel compounds on metabolism remains 
an important area of research both for potentially developing new treatment 
approaches and options, and in furthering knowledge of metabolic regulation. 
A major consequence of insulin resistance is inadequate peripheral glucose 
disposal. Skeletal muscle tissue is one of the targets of insulin and it is responsible for 
~80% of glucose uptake in the post-prandial state making this tissue an important 
treatment target (53). The flavonoid naringenin has been reported to have antioxidant, 
antiproliferative, anticancer, and anti-inflammatory properties (1,22,92) and exhibits 
effects on glucose and lipid metabolism. In vitro naringenin has been shown to 
decrease basal oleate-stimulateg apoliprotein B secretion in hepatocytes (7,8,9). In in 
vivo naringenin exhibited a hypoglycaemic effect in male wistar rats, and in 
streptozotocin-induced diabetic rats naringenin treatment significantly decreased 
plasma glucose, triglycerides and total cholesterol levels (18,17). Furthermore 
naringenin has structural similarities with the extensively researched resveratrol and 
the many benefits of red wine, a particularly rich source of the compound, may be 
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attributable to it. Resveratrol has been shown in recent years to have antidiabetic 
effects. Studies by our group (11) and others (3.1,4,65,93,112.1) have shown that 
resveratrol increases glucose uptake by skeletal muscle cells and also prevents fatty 
acid-induced insulin resistance in vitro and in vivo. There are no studies examining 
the effects of naringenin on glucose uptake in skeletal muscle cells which is the focus 
of the present work. 
Hypothesis 
The hypothesis of the present work is that naringenin has an insulin-like effect of 
increasing glucose uptake in skeletal muscle cells and/or potentiates the effect of 
insulin. 
Specific Aims: 
1) Determine the effects of naringenin on basal and insulin-stimulated glucose 
uptake in skeletal muscle cells. 
2) Elucidate the mechanism of naringenin-stimulated glucose transport in 
skeletal muscle cells by examining effects on signalling molecules involved or 
suspected of being involved in glucose uptake regulation in skeletal muscle. 
These aims are addressed by examining the effects of naringenin on glucose uptake, 
and on signalling molecules including Akt, PI3K, AMPK, SIRTl, and CaMKK. 
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CHAPTER 3: RESEARCH DESIGN AND METHODS 
3.1 Materials 
Minimum essential medium (u-MEM), fetal bovine serum (FBS), trypsin, and 
antibiotic were purchased from GIBCO Life Technologies (Burlington, ON, Canada). 
FBS was later purchased from HyClone, ThermoFisher Scientific (Ottawa, ON, 
Canada). Specific antibodies against Akt, phospho-Akt ser473, phosphor-Akt thr308, 
AMPKu, phosphor-AMPKu thr172, HRP-conjugated anti-rabbit secondary antibody, 
and HRP-conjugated anti-mouse were purchased from New England Biolabs 
(Mississauga, ON, Canada). ChemiGLO reagents were purchased from VWR 
(Mississauga, ON, Canada). Polyvinylidene difluoride (PVDF) membranes, 
molecular weight protein standards, and electrophoresis reagents were purchased 
from BioRad (Mississauga, ON, Canada). eHJ2- deoxy-D-glucose, was purchased 
from PerkinElmer (Boston, MA). Cytochalasin B (CB), wortmannin, and Compound 
C were purchased from Calbiochem (Gibbstown, NJ, US). The sirtuin inhibitor 
Ex527 was purchased from Tocris Bioscience (Ellisville, MO, US). The inhibitor of 
calciumlcalmodulin-~ependent protein kinase kinase (CaM-KK). STO-609, was a 
kind gift from Dr. Bilan (Hospital for Sick Children, Toronto, ON, Canada). The 
SIRTI activity assay kit was- purchased from BIOMOL International (Plymouth 
Meeting, P A, US). All other chemicals, including naringenin, nicotinamide, bovine 
serum albumin, and cold 2-deoxy-D-glucose, were purchased from Sigma Chemicals 
(St. Louis, MO, US). The parental L6 cells were a kind gift from Dr. A. Klip 
(Hospital for Sick Children, Toronto, ON, Canada). 
3.2 Preparation of Buffers and Solutions 
Glucose Uptake Assay: 
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HEPES Buffer Saline (HBS) Washing Buffer: 140 mM NaCI, 5mM KCI, 20mM 
HEPES, 2.5mM MgS04, 1 mM CaCh. Dilute with distilled (DD) water and fill to 800 
ml, adjust pH to 7.4 and then fill to 1 L with DD water. 
0.9% NaCl: Add 0.9g NaCI per 100 ml DD water. 
0.05N NaOH: Add 1 ml 5N NaOH to 99 ml DD water. 
Total Radioactive Buffer: In HBS buffer dilute 1:1000 hot eH]2-deoxy-D-glucose, 
and 1-1000 cold 2-deoxy-D-glucose. E.g. for 10 ml of HBS, add 1 0 ~l of hot eH]2-
deoxy-D-glucose and 1 0 ~l of cold 2-deoxy-D-glucose. 
Non-specific Radioactive Buffer: Use total radioactive buffer and add 1: 1 000 
cytochalasin B. 
Cell Lysis: 
Phosphate buffer saline (PBS) Washing Buffer: 137 mM NaCI , 2.7mM KCI, 1.5 mM 
KH2P04, 8.1 mM Na2HP04, 0.68mM CaCb, 0.49mM MgCb, add water to 1 Land 
adjust pH to 7.4. 
Sodium dodecyl sulphate (SDS) Sample Buffer: 62.5mM Tris-HCI (pH 6.8), 2% w/v 
SDS, 10% glycerol, 0.01 % bro.mophenol blue, add 0.05% ~-mercaptoethanol before 
use. 
E.g. for a 200 ml 3X SDS sample buffer: 60 ml glycerol, 37.5 ml1.0 M Tris (pH 6.8), 
12 g SDS, pure water to 200 ml, 60mg bromphenol blue. 
N aringenin 47 
Cell Lysis Buffer: 20mM Tris (pH 7.5),150 mM NaCI, 1 mM EDTA, 1 mM EGTA, 
1% Triton X-I00, 2.5mM sodium pyrophosphate, 1 mM ~-glycerolphosphate, 1 mM 
Na3V04, 1 Ilglmlleupeptin, add 1 mM PM SF before use and chill on ice. 
Western Blot Analysis: 
lOx Tris-buffered saline (TBS): 24.2 g Tris base, 80 g NaCI, add water to 1 Land 
adjust pH to 7.6. 
Blocking Buffer (for 2 membranes): 7.5 ml lOx TBS, 67.5 ml water, 3.75 g nonfat 
dry milk, and then add 75 III Tween-20. Prepare fresh daily. 
Primary Antibody Dilution Buffer: 2 ml lOx TBS, 18 ml water, 1.0 g BSA, and then 
add 20 III Tween-20. Store at 4°C. 
Wash Buffer TBS/T: Ix TBS, 0.1% Tween-20. E.g. 450 ml water, 50 ml lOx TBS, 
and 500 III Tween-20. 
lOx Electrode Running Buffer: 15.15 g Tris base, 72 g Glycine, 5.0 g SDS. Dissolve 
and bring the volume to 500 ml with water. Before use dilute 50 ml of lOx stock with 
450 ml water. Store at 4°C. 
Transfer Buffer: To make 1 L use 3.03g of 25 mM Tris base, 15.01 g of 0.2 M 
Glycine, 200 ml of 100% methanol and 800 ml of water. Make fresh daily and chill at 
4°C before use. 
3.3 The L6 Skeletal Muscle Cell Line 
The L6 cell line was prepared from the thigh muscle of newborn rats and 
consists of mononucleated myoblasts that retain myogenic potential; a characteristic 
that is inherited by their progeny (125). These myoblasts proliferate at high (10%) 
serum and can be induced to spontaneously fuse and differentiate into elongated, 
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multinucleated, postmitotic, contracting 
myotubes (125) when grown to 
confluence and in low (2%) serum 
concentration (6). At the differentiated 
stage L6 share some of the biochemical, 
morphological, electrical, contractile, 
and metabolic characteristics of in vivo 
skeletal muscle (6,58,78). L6 myotubes 
express the insulin and IGF-l receptors 
which exhibit selectivity for their 
ligands, and other proteins known to be 
Figure 6: The L6 skeletal muscle cell 
involved in insulin signalling in skeletal line. Top: myoblasts. Bottom: 
Myotubes. Courtesy of Dr Evangelia 
muscle including GLUT4 glucose Tsiani 
transporters, IRS-I , PI3K, and Akt (48). The differentiated cells respond to insulin 
and IGF-l by an increase in glucose uptake. Acute insulin treatment stimulates 
glucose uptake with 100 nM insulin treatment reaching a maximal effect of 1.6- to 2-
fold above basal within 15 minutes. After the initial response to insulin stimulation 
there is a second phase of increased glucose uptake that follows after 2 hours. (58). 
The glucose uptake in L6 is mediated by facilitated diffusion through plasma 
membrane transporters. The L6 express GLUTl, GLUT3, and GLUT4 isoforms of 
the transporters but their expression is dependent on the developmental stage of the 
cells. The ubiquitous GLUTI transporter is expressed in both myoblasts and 
myotubes but the levels decrease during cell differentiation and its main role appears 
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to be in basal glucose uptake (78,6,58). The GLUTl proteins also become less 
glycosylated in myotubes (58) which appears to be important for a GLUTl structure 
with higher affinity for glucose and therefore for maintaining high transporter activity 
(2). The GLUT4 isoform appears to be only expressed to significant levels upon 
differentiation and is the main contributor to insulin-stimulated glucose uptake 
(58,6,78). The GLUT3 isoform is expressed in both myoblasts and myotubes with 
only slightly increased levels in myotubes (6,58). GLUT3 is an isoform founds in 
human fetal skeletal muscle and brain, and only at very low levels in adult muscle. 
The fact that it is present in L6 myotubes is suggested to be due to the fetal/neonatal 
characteristic of L6 (6). GLUTl and GLUT3 levels are concentrated at the plasma 
membrane while GLUT4 is mostly located in the intracellular stores. Upon insulin 
stimulation all three isoforms are translocated to the plasma membrane but the largest 
relative change occurs with the GLUT4 (58). As might be expected from the 
differences in GLUT expression between myoblasts and myotubes glucose transport 
activity also differs as the cells develop. Basal glucose transport is highest in 
myoblasts and decreases as the cells differentiate into myotubes while insulin-
stimulated glucose uptake is observed only upon cell alignment and increases as they 
differentiate to the myotube stage (78). 
Culture cells provide the benefit of working with a homogenous group of cells 
limiting the possibility that variations in response are due to having different types of 
cells with different responses in each sample as is the case in vivo where a certain 
tissue is composed of different cell types (105). It is also a system which allows the 
researcher to tightly control the external environment of the cell population thereby 
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avoiding all the factors seen in vivo (e.g. extracellular matrix, blood) that may playa 
role in the treatment response. Other benefits of cultured cells is that they are more 
viable than isolated skeletal muscle from biopsies, and the technique is not invasive in 
nature (105). A particular benefit of using L6 to other models of cultured skeletal 
muscle is that these cells are well established in expressing the functional GLUT4 
transporters and respond well to insulin by causing GLUT4 translocation from an 
intracellular storage site to the plasma membrane (105,58). The rat L6 skeletal muscle 
cell line is a well-established in vitro model of skeletal muscle which is widely used 
in studies of insulin signalling and glucose transport. 
3.4 Preparation of Treatment Compounds 
Naringenin: 
For a 100 mM stock solution: weigh 0.0272g of naringenin and dissolve in 1 ml of 
ethanol. Vortex and store at 4C. On day of treatment prepare a working stock of 1 
mM: Add 10 III of 100 mM stock per 990111 of 0% FBS media. E.g. Add 100 Ill/well 
of 1 mM working stock for a final [100 11M]. 
Insulin: 
Initial solution concentration is 60mM ([100 U/ml]). For a 20mM stock solution: add 
100 III of initial solution to 200111 of 2% FBS media. Store at 4C. For a final [100 
nM] add Sill/well (containing 1 ml media). 
Nicotinamide: 
For a 300mM stock weigh 0.04g of nicotinamide and dissolve in 1092 III DD water. 
Store at 4C. For a final [6mM] add 20111 of300mM stock/ml into wells. 
STO-609: 
Initial solution is 10 mM. For a final [27).1M] add 2.7).11/ml into wells. 
Ex527: 
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For a 10 mM stock dissolve 10 mg in 3949).11 of DMSO. Protect from light and store 
at -20C or lower. On day of treatment prepare a 1 mM working stock by adding 10 
).11 of 10 mM stock per 90).11 of 0% FBS media. For a final [10 ).1M] add 10 ).11 of 1 
mM stock/ml into wells. 
3.5 Cell Culture and 2-deoxy-D-glucose Uptake 
L6 rat skeletal muscle cells were grown for 2 days in a-MEM containing 
5mM glucose, 10% (v/v) FBS, and 1 % (v/v) antibiotic-antimycotic solution (100 
U/ml penicillin, 100 ).1g/ml streptomycin, and 250 ng/ml amphotericin B). The cells 
were then placed in 2% FBS containing media and allowed to differentiate into 
myotubes. Both myoblasts and myotubes were used depending on the experiments. 
The cells were serum deprived by placing them in 0% media for 3-5 hours before 
treatments. The final concentration and the time of incubation for each compound are 
indicated in each figure (a vehicle control group was used in parallel with the 
treatment groups). Cells were grown in 6-well plates for western blot experiments and 
in 12-well plates for glucose uptake experiments. For glucose uptake measurements at 
the end of treatment, cells were. rinsed 3x with HBS at room temperature followed by 
2-eH]deoxy-D-glucose uptake measurements by incubating the cells with 300).11 of 
total radioactive buffer in triplicates. Non-specific glucose uptake was assayed using 
cytochalasin B in a fourth well. The cells were allowed to uptake glucose for 10 
minutes at room temperature after which glucose uptake was stopped by washing 3x 
with cold 0.9% NaCl solution (1 ml/well) followed by lysis by addition of 1 mllwell 
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of 0.05N NaOH. Prior to lysis cells were examined by microscopic observation. 
Radioactivity within cells was determined by scintillation counting. Specific glucose 
uptake (i.e. via glucose transporters) was determined by the following equation where 
Total is the mean count of three wells: 
Specific = Total- Non Specific 
3.6 Western blotting 
At the end of the treatment period, the cells were rinsed with PBS (1 mllwell) 
and then lysis buffer (100 Ill/well of a 6-well plate) was added, and the lysate was 
scraped off and stored in eppendorf tubes (1.5 ml). The protein content in each 
sample was assessed using the BioRad assay. A 3x electrophoresis sample buffer was 
used to solubilize the lysates. After the addition of the electrophoresis sample buffer 
the samples were boiled for 5 minutes and stored at -20°C. Protein samples were 
loaded into wells of a 10% SDS- polyacrylamide gel and separated by electrophoresis 
at l20V for ~2 hours. The samples were subsequently transferred from gel to a PVDF 
membranes at 100V for 1 hour. After transfer the membranes were washed for 5 
minutes with 25 ml lxTBS followed by incubation for 1 hour at room temperature in 
agitator with 10 ml of 5% (w/v) nonfat dry milk in Tris- buffered saline. Afterwards 
the membranes were rinsed wi~h 25 ml ofTBS/T and then overnight at 4°C with the 
primary antibody diluted (1: 1 000) in primary antibody dilution buffer with gentle 
agitation. The following primary polyc1onal antibodies were used: Phospho- Akt 
(Ser473 and Thr308), Total- Akt, Phospho- AMPK (Thr172), Total-AMPK. The next 
day the membranes were washed 3x for 5 minutes with 15 ml TBS/T, and the primary 
antibody was detected with HRP-conjugated secondary antibody diluted in blocking 
buffer (l :2000) which was incubated with the membrane for at least an hour at room 
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temperature. This was followed by washing the membranes 3x for 5 minutes with 
TBS/T and the secondary antibody was detected by ChemiGLO reagent and 
visualized by FluroChem software via an autodeveloper (ThermoFisher). 
3.7 Statistical Analysis 
The results are presented as mean ± SE of the indicated number of separate 
experiments using student' s paired t-test or analysis of variance (ANOVA) followed 
by Tukey's test. Statistical significance was assumed at P<O.05. Statistical analysis 
was performed using SPSS v16.0 software for paired t-test, while analysis of variance 
(ANOVA) was performed using SAS v9.0 software or SPSS v16.0 software. 
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CHAPTER 4: RESULTS 
4.1 Dose- and time- dependent effects of naringenin on glucose uptake in L6 
skeletal muscle. 
We investigated whether nanngenm may stimulate glucose uptake in L6 
skeletal muscle cells. For this purpose L6 myotubes were treated with 10, 20, 50, 75, 
100, and 150 IlM for 120 minutes followed by glucose uptake measurements (Figure 
7 A). An incubation time of 120 minutes was initially chosen based on previous 
studies done in our lab with another polyphenolic compound, resveratrol, which 
indicated such treatment significantly increased glucose uptake. Naringenin at 5 and 
25 IlM did not have a significant effect on glucose uptake (93±3.5% and 108±12.5% 
of control, P>0.05 respectively). However, at 50 IlM naringenin significantly 
increased glucose uptake (141±5.5% of untreated control, P<0.5, Figure 7A). 
Maximum stimulation was observed at 75 IlM (165±4.9% of control, P<O.OI). The 
effect of naringenin reached stability at higher concentrations (100 IlM and 150 IlM) 
and did not further increase glucose uptake. 
Next, t6 examine whether the effect of naringenin to increase glucose uptake 
in myotubes is time-dependent, the cells where incubated with 75 IlM of naringenin 
for 15, 30, 60, 90, 120, 1~0, and 180 minutes followed by glucose uptake 
measurements (Figure 7B). Incubation of myotubes with naringenin for 15 and 30 
minutes did not result in a significant increase in glucose uptake. However, a 
significant response was seen at 60 minutes and a maximum response at 120 minutes 
stimulation (144±8.7%, P<0.05, and 168±20.1 %, P<0.05, respectively, Figure 7B). 
Visual microscopic examination showed that cell morphology was not affected by 
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treatments. Importantly, the effect of naringenin on glucose uptake in myotubes 
achieved the same level as seen with maximum insulin (100 nM, 30 minutes) 
stimulation (192.8±24%, P<O.Ol and 190.1 ±13.3%, P<O.OOl, respectively, Figure 8). 
These results suggest that naringenin significantly stimulates glucose uptake in a 
dose- and time-dependent manner that is independent of insulin. Insulin' s effect to 
increase glucose uptake in muscle is largely mediated by GLUT4 transporters, 
therefore to investigate whether a similar mechanism may be involved in the 
naringenin-stimulated increase in glucose uptake we also examined whether 
naringenin increases glucose uptake in L6 myoblasts. As the L6 cell line 
differentiates from myoblast to myotubes they differ also in the degree of GLUTI and 
GLUT4 transporter expression. L6 myoblasts are known not to respond to insulin due 
to low GLUT4 expression. Similar to insulin, treatment with naringenin did not 
significantly increase glucose uptake in L6 myoblasts (122.3±11.8% and 
106.3±15.2%, respectively, P>0.05, Figure 8), indicating that the effect of naringenin 
to increase glucose uptake in myotubes may be due to modulation of GLUT4 
translocation and/or activity. 
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Figure 7: (A) Effects of naringenin on 2DG uptake by skeletal muscle cells: Dose 
Response. L6 myotubes were incubated with the indicated concentrations of 
naringenin for 120 minutes at 37°C. (B) Effects of naringenin on 2DG uptake by 
skeletal muscle cells: Time Course. L6 myotubes were incubated with 75JlM 
naringenin for the indicated time periods at 37°C. At end of treatments 2DG uptake 
was performed. Results are the mean ± SE of 2-5 experiments expressed as percent of 
control. *P< 0.05, ** P<O.Ol, ***P<O.OOl. 
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Figure 8: Effects of naringenin and insulin on 2DG uptake by myotubes (dark bars) 
and myoblast (light bars). L6 JIlyotubes were incubated with or without 100 nM 
insulin (1) for 30 minutes or 75 )lM concentrations of naringenin for 2 hours at 37°C. 
At end of treatments 2DG uptake was performed. Results are the mean ± SE of 10 
experiments (dark bars) and ± SE of 3 experiments (light bars) expressed as percent 
of control. *P< 0.05, ** P<O.Ol , ***P<O.OOl. 
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4.2 Effects of naringenin on insulin-stimulated glucose uptake. 
In addition to naringenin's effect alone we also investigated whether 
naringenin would have an additive effect on glucose uptake when combined with 
acute insulin stimulation. To this effect myotubes were treated with or without 100 
IlM of naringenin (120 minutes total incubation) and with or without varying 
concentrations of insulin for the last 30 minutes. Insulin concentrations included 1 
nM, 3 nM, 10 nM, and 100 nM. Glucose uptake measurements were performed 
following treatments. 
Insulin dose-dependently increased glucose uptake (134±1.8%, 167±9.8%, 
192±4.9%, 207± 1 0.6% of control, in order of increasing concentration) (Figure 9). 
Pre-treatment with naringenin significantly increased glucose uptake for the sub-
maximal insulin treatment groups (1 nM, 3 nM, 10 nM) as compared to treatment 
with insulin alone (214±11.6%, 233±0.9%, 244±6.4% of control, in order of 
increasing insulin concentration) (Figure 9). With maximal levels of insulin 
naringenin's capacity to further increase glucose uptake tended to be additive but did 
not reach significantly increased levels above insulin treatment alone (252±5.6% vs. 
207±10.6% of control, respectively, p=0.093) (Figure 9). The results indicate that 
naringenin has an additive effec! on the insulin-stimulated glucose uptake only at sub-
maximal concentrations of insulin. 
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Figure 9: Naringenin has an additive effect on the insulin stimulated glucose uptake 
in myotubes. L6 myotubes were serum deprived for 3-5 hours and then pre-treated 
with 1 00 ~M naringenin for 90 minutes followed by treatment with or without 
various concentrations of insulin for 30 minutes at 37°C. At end of treatments 2DG 
uptake was performed. Results are the mean ± SE of 3 experiments expressed as 
percent of control. 
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4.3 Effects of naringenin on Akt phosphorylation at Ser473 and Thr308. 
In order to elucidate the mechanism of the naringenin-mediated increase in 
glucose uptake, given the similarity of naringenin's effect with that of insulin, we 
next examined the effect of naringenin on Akt, a molecule involved in the insulin 
signalling cascade leading to increased glucose uptake in myotubes. The activity of 
Akt is regulated by phosphorylation and the phosphorylation at two of its residues -
Ser473 and Thr308 - is required for its activation within this pathway (55,114). The 
effect of naringenin on the phosphorylation of these two residues was examined using 
phospho-specific antibodies in western blot analysis. As expected, insulin treatment 
(100 nM for 15 minutes) strongly stimulated phosphorylation of both Ser473 and 
Thr308 Akt residues (367±12.5%, P<0.05, and 262.5±7.5%, P<0.05, Figure lOA). 
However, treatment with 100 )lM ofnaringenin for 15, 30, 60, or 120 minutes did not 
increase the phosphorylation of either of the Akt residues (Figure lOA). 
Although naringenin did not affect basal Akt phosphorylation the possibility 
existed that the observed additive effect of naringenin on insulin-stimulated glucose 
uptake may be modulated by potentiating the insulin-stimulated Akt phosphorylation. 
To examine this possibility L6 myotubes were treated with or without 100 )lM of 
naringenin, followed by treatmep.t with or without different concentrations of insulin 
(1 nM, 10 nM, 100 nM). As expected, insulin treatment increased Akt 
phosphorylation at Ser473 (Figure lOB) and tended to increase Akt phosphorylation 
at Thr308 (Figure 10C). However, pre-treatment with naringenin did not significantly 
affect the insulin-stimulated Akt phosphorylation (Figure 10B,C). These results 
suggest that the effect of naringenin on glucose uptake is Akt -independent. 
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Figure 10: (A) Time-course: Effects of naringenin on Akt phosphorylation/activation 
in skeletal muscle. L6 myotubes were serum deprived for 3-5 hours and then 
incubated with 100 nM insulin and/or 1 00 ~M naringenin for the indicated time in 
minutes. After treatment total celllysates were prepared and resolved by SDS-PAGE 
and immunoblotted with specific anti-bodies that recognize phospho-Akt (Ser473 and 
Thr308) and total-Akt. Results are the mean ± SE of 3-5 experiments expressed as 
percent of control. *p< 0.05 compared to untreated control. 
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Figure 10: (B) Effects of naringenin on insulin-stimulated Akt phosphorylation at 
Ser473 in skeletal muscle. L6 myotubes were serum deprived for 3-5 hours and then 
pre-treated with 100 ).lM naringenin for 30 minutes followed by treatment with or 
without various concentrations of insulin for 15 minutes. After treatment total cell 
lysates were prepared and resolved by SDS-P AGE and immunoblotted with specific 
anti-bodies that recognize phospho-Akt and total-Akt. *p< 0.05, ** p<O.OI, 
***p<O.OOI compared to untreated control, #p<0.05, ##p<O.OI, ###p<O.OOI 
compared to insulin treatment alone. 
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Figure 10: (C) Effects of naringenin on insulin-stimulated Akt phosphorylation at 
Thr308 in skeletal muscle. L6 myotubes were serum deprived for 3-5 hours and then 
pre-treated with 100 f.lM naringenin for 30 minutes followed by treatment with or 
without various concentrations of insulin for 15 minutes. After treatment total cell 
lysates were prepared and resolved by SDS-P AGE and immunoblotted with specific 
anti-bodies that recognize phospho-Akt and total-Akt. 
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4.4 Effects of PI3K inhibition on naringenin-stimulated glucose uptake. 
PI3K has been established as a key molecule involved in the insulin signalling 
cascade that leads to glucose uptake in skeletal muscle and its activity is required in 
this action (15.1 ,55,91). Therefore we investigated whether PI3K may also be a 
mediator of naringenin-stimulated glucose uptake by using a PI3K inhibitor, 
wortmannin. Myotubes were pre-treated with 1 ~M of wortmannin for 15 minutes 
followed by treatment with or without 100 ~M naringenin for 120 minutes or 100 nM 
insulin for 30 minutes. After treatments glucose uptake measurements were 
performed. The insulin- and naringenin-stimulated increase in glucose uptake 
(235±12.4% and 212±27.1%, p<O.OOl and p<O.Ol, respectively) was inhibited with 
wortmannin pre-treatment (120±13% and 123±15.7% of control, p<O.OOl compared 
to insulin or naringenin alone, respectively) (Figure 11A). These results suggest that 
PI3K is involved in the regulation of glucose uptake by naringenin. To confirm the 
effectiveness of wortmannin to inhibit PI3K we examined its effect on 
phosphorylation of Akt of insulin treated cells, as Akt is a molecule downstream of 
PI3K in the insulin-signalling cascade. Treatment of myotubes with 100 nM insulin 
for 15 minutes significantly increased Akt phosphorylation (4679±434% of control, 
p<0.05) and pre-treatment wit~ 1 ~M of wortmannin for 15 minutes significantly 
inhibited this phosphorylation (83±5.5% of control, p<0.05) which would indicate 
that wortmannin had successfully inhibited insulin signalling (Figure lIB). 
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Figure 11: (A) Effect of PI3K inhibition on insulin- and naringenin-stimulated 
glucose uptake: L6 myotubes were serum deprived for 3-5 hours and then incubated 
with 1 llM of wortmannin for 15 minutes followed by treatment with 100 nM insulin 
for 30 min or 100 llM naringenin for 2 hours. At end of treatments 2DG uptake was 
performed. Results are the mean ± SE of 8 experiments expressed as percent of 
control. *p< 0.05, ** p<O.OI, ***p<O.OOI compared to untreated control, #p<0.05, 
##p<0.01, ###p<O.OOI compared to insulin or naringenin treatment alone. 
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Figure 11: (B) Effects of wortmann in on insulin-stimulated Akt phosphorylation: L6 
myotubes were serum deprived for 3-5 hours and then pre-treated with 1 )lM of 
wortmannin followed by treatment with 100 nM insulin for 15 minutes. After 
treatment total cell lysates were prepared and resolved by SDS-PAGE and 
immunoblotted with specific anti-bodies that recognize phospho-Akt and total Akt. 
** p<O.OI compared to untreated control, ##p<O.Ol compared to insulin treatment 
alone. 
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4.5 Effects of naringenin on AMPK phosphorylation. 
AMPK in skeletal muscle has been shown to be another mechanism 
stimulating glucose uptake. It is activated by exercise/contraction and numerous 
compounds including metformin, thiazolidineones, and the polyphenol resveratrol 
(13,28,35,84,110,126). Since resveratrol, which has structural similarities with 
naringenin, has been reported to activate AMPK the effect of naringenin on AMPK 
phosphorylation was also examined as a potential mechanism for its glucose uptake 
stimulating effect. Myotubes were treated with or without 100 )lM naringenin for 15, 
30, 60, and 120 minutes. Western blot analysis showed that naringenin treatment 
increased AMPK phosphorylation (Figure 12). A significant increase in AMPK 
phosphorylation was observed within 15 minutes of naringenin treatment 
(153.2±16.3%, P<0.05) and peak levels were observed within 60 minutes 
(190.4±23.9%, P<0.05) and remained elevated at 120 minutes (178±23.4%, P<0.05). 
As expected, insulin did not significantly increase AMPK phosphorylation 
(113±13%, P>0.05, Figure 12). 
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Figure 12: Time-course: Effects of naringenin on AMPK phosphorylation/activation 
in skeletal muscle. L6 myotubes were serum deprived for 3-5 hours and then 
incubated with 100 nM insulin or 100 f.lM naringenin for the indicated time (minutes). 
After treatment total cell lysates were prepared and resolved by SDS-PAGE and 
immunoblotted with specific anti-bodies that recognize phospho-AMPK (Thr172) and 
total-AMPK. Results are the mean ± SE of 5 experiments expressed as percent of 
control. *p< 0.05 compared to untreated control. 
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4.6 Effects of PI3K inhibition on naringenin-stimulated AMPK phosphorylation. 
Because activation of AMPK is known to lead to increased glucose uptake in 
skeletal muscle and so far the results indicate that naringenin activates AMPK and 
that PI3K appears to be involved in the naringenin-stimulated glucose uptake we were 
interested in examining whether PI3K inhibition would inhibit naringenin-stimulated 
AMPK phosphorylation. Myotubes were pre-treated with or without 1 flM of 
wortmannin for IS minutes followed by treatment with or without 100 flM naringenin 
for 60 minutes. Western blot analysis revealed that naringenin treatment stimulated 
AMPK phosphorylation (l83±21.S9% of control) and pre-treatment with wortmannin 
did not inhibit the naringenin-mediated AMPK phosphorylation but rather tended to 
have an additive effect (27S±49.7%) (Figure l3). These results suggest that PI3K is 
not an upstream mediator of naringenin-induced AMPK phosphorylation. 
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Figure 13: Effects of PI3K inhibition on naringenin-mediated AMPK 
phosphorylation. L6 myotubes were serum deprived for 3-5 hours and then pre-
treated with 1 )lM of wortmannin followed by treatment with 100 )lM naringenin for 
60 minutes. After treatment total cell lysates were prepared and resolved by SDS-
PAGE and immunoblotted with specific anti-bodies that recognize phospho-AMPK 
(Thr172) and total-AMPK. Results are the mean ± SE of 4 experiments expressed as 
percent of control. *p< 0.05 compared to untreated control. 
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4.7 Effects of SIRTI inhibition on naringenin-stimulated glucose uptake and on 
phosphorylation of AMPK and LKBI. 
Recent reports indicate that activation of the protein deacetylase SIRT1 may 
lead to AMPK phosphorylation by increasing phosphorylation/activation ofLKB1, an 
upstream kinase of AMPK (66). Additionally SIRT1 has recently been implicated in 
the mechanism of the structurally similar resveratrol to increase AMPK 
phosphorylation (46). We therefore hypothesized that SIRTI may mediate the effect 
of naringenin to stimulate AMPK phosphorylation and thereby mediate glucose 
uptake in skeletal muscle cells. Furthermore, SIRTI may lead to increased activity of 
LKBI which may mediate its effect on AMPK. To test this hypothesis we conducted 
experiments using SIRT1 inhibitors, nicotinamide and Ex527. The inhibitory mode of 
action of nicotinamide is via product inhibition. The deacetylation activity of SIRTI 
requires bond cleavage between the ADP-ribose and nicotinamide portions of NAD. 
This releases nicotinamide which can rebind to reform NAD thereby reversing the 
deacetylation reaction. Nicotinamide accumulation favours reformation of NAD 
thereby inhibiting SIRT1 (87). Ex 527 is a cell permeable, potent, and selective 
inhibitor of SIRT1 that appears to work by binding to the enzyme after the release of 
nicotinamide and prevent the re!ease of the deacetylated substrate (87). 
First, we examined the effect of SIRTI inhibition on naringenin-stimulated 
glucose uptake. Myotubes were pre-treated with either 6 mM nicotinamide for 4 
hours or 10 ~M Ex527 for 12 hours followed by treatment with or without 100 ~M 
naringenin for 2 hours. As expected, naringenin increased glucose uptake 
(182± 12.2% of control, p<O.OO 1, Figure 14 A,B). However, neither nicotinamide or 
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Ex527 inhibited glucose uptake by naringenin (162±15.2% and 176±5.4% of control, 
respectively, Figure 14A,B) suggesting that SIRT1 is not involved in the mechanism 
of naringenin on glucose uptake. Although SIRT1 inhibitors had no effect on 
naringenin-mediated glucose uptake the possibility still existed that SIRT1 may be 
involved in mediating naringenin' s effect on AMPK. If so this would rule out AMPK 
as a mediator of naringenin's effect on glucose uptake. Therefore, myotubes were 
incubated with either 6mM nicotinamide for 4hours or 10 )lM Ex527 for 12 hours 
followed by treatment with 100 )lM naringenin for 60 minutes. Western blot analysis 
showed that naringenin increased AMPK phosphorylation (191±23.3% of control and 
697±323.6% of control, Figure 14C and D, respectively). SIRT1 inhibition by either 
nicotinamide or Ex527 did not inhibit AMPK phosphorylation, tending rather to 
increase AMPK phosphorylation. As shown in Figure 14D naringenin treatment had 
no effect on the phosphorylation ofLKB1 nor did SIRT1 inhibition by Ex527. 
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Figure 14: (A,B) Effects of SIRTI inhibitors on naringenin mediated glucose uptake. 
(A) L6 myotubes were serum deprived and pre-treated with 6mM nicotinamide for 4 
hours before incubating with 100 /-lM naringenin for 2 hours. (B) L6 myotubes were 
serum deprived and pre-treated with 10 /-lM Ex527 for 12 hours before incubating 
with 100 /-lM naringenin for 2h. At end of treatments 2DG uptake was performed. 
Results are the mean ± SE of 5 experiments expressed as percent of control. *p< 0.05, 
** p<O.OI, ***p<O.OOI compared to untreated control. 
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Figure 14: (C) L6 myotubes were serum deprived and pre-treated with 6 mM 
nicotinamide for 4 hours before incubating with 1 00 ~M naringenin for 1 hour. (D) 
L6 myotubes were serum deprived and pre-treated with 10 ~M Ex527 for 12 hours 
before incubating with 1 00 ~M naringenin for 1 hour. After treatment total cell 
lysates were prepared and resolved by SDS-PAGE and immunoblotted with specific 
anti-bodies that recognize phospho-AMPK (Thr172), total-AMPK, and phospho-
LKB 1. Representative blots of 3 experiments. 
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4.8 Effects of AMPK inhibitors on naringenin mediated glucose uptake. 
Activation of AMPK has been shown to lead to increased glucose uptake in 
several cell types and this molecule has been shown to be involved in the therapeutic 
effects of exercise, contraction, and anti-diabetic agents on metabolism. Our data 
indicates that naringenin stimulates AMPK phosphorylation therefore we 
hypothesized that here too AMPK activity may mediate the increase in glucose 
uptake. Due to its nature as an energy sensor and regulator the AMPK molecule 
appears to have multiple ways of being activated. SIRTI is a newly identified 
potential activator of AMPK but it is only one of the possible ways AMPK may be 
stimulated. In the case of naringenin our data would suggest that SIRTI is not 
involved; here is one example in which the two polyphenols, naringenin and 
resveratrol, seem to differ. To further test our hypothesis we sought other ways to 
pharmacologically inhibit AMPK activity and test the effects on naringenin-
stimulated glucose uptake. Two other ways that AMPK is activated is by a cellular 
increase in AMP: ATP ratio and by the upstream activator of AMPK calmadulin-
dependent protein kinase kinase (CaMKK) (35,31,13). Activation of CaMKK is not 
mediated by increasing the AMP: ATP ratio but rather by a rise in calcium (25,31). 
We therefore used compound _C (CC), an ATP-competitive AMPK inhibitor, and 
STO-609, an inhibitor ofCaMKK, to examine their effect on naringenin-stimulated 
glucose uptake. STO-609 is a cell permeable and selective inhibitor of CaMKK a and 
~ isoforms that is reported to work by competitive inhibition of A TP (115). 
Myotubes were pre-treated with 25 f.lM CC for 30 minutes followed by 
treatment with or without 100 f.lM naringenin for 2 hours (Figure 15A). As expected 
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naringenin increased glucose uptake (187±10.5% of control, p<O.Ol, Figure 15A), 
however pre-treatment with CC did not inhibit this glucose uptake. Myotubes were 
also pre-treated with 27 f.!M STO-609 for 60 minutes followed by treatment with 100 
f.!M naringenin for 2 hours (Figure 15B). Again naringenin significantly increased 
glucose uptake (184±5.6% of control, p<O.Ol). As was the case with CC, STO-609 
pre-treatment did not inhibit the naringenin-stimulated glucose uptake, tending to 
retain similar levels as naringenin treatment alone (180±23.5% of control, p=0.077, 
Figure 15B). Although these results do not rule out AMPK's involvement in the 
naringenin effect on glucose uptake, because there could be other ways of AMPK 
activation, they do bring its involvement into doubt. The results suggest that either 
AMPK is not involved or that naringenin activates AMPK via a mechanism that does 
not involve SIRTl, CaMKK, or changes in AMP:ATP ratio. 
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Figure 15: Effects of AMPK inhibitors on naringenin mediated glucose uptake. (A) 
L6 myotubes were serum deprived and pre-treated with 25 flM CC for 30 min 
followed by treatment with or without 100 flM naringenin for 2h. At end of 
treatments eH] 2-deoxy-D glucose uptake was performed. Results are the mean ± SE 
of 4 experiments expressed as percent of control. (B) L6 myotubes were serum 
deprived and pre-treated with 27 flM STO-609 for 60 min followed by treatment with 
100 flM naringenin for 2h. At end of treatments 2DG uptake -was performed. Results 
are the mean ± SE of 3 experiments expressed as percent of control. *p< 0.05, ** 
p<O.Ol, ***p<O.OOI compared to untreated control. 
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4.9 Effects of Compound C on naringenin-stimulated AMPK phosphorylation. 
From previous results further elucidation was necessary of the role of AMPK 
in the naringenin-stimulated glucose uptake. We sought to determine whether the 
phosphorylation of AMPK by naringenin would be inhibited by cc. This would shed 
light also on whether the phosphorylation of AMPK in this case may involve an 
increase in AMP:ATP ratio. Myotubes were pre-treated with 25 /lM CC for 30 
minutes followed by treatment with 100 /lM naringenin for 60 minutes or 2 mM 
AICAR for 2 hours. AICAR (5-Aminoimidazole-4-carboxyamide ribonucleoside) is 
an analog of adenosine which, when taken up into myotubes is converted to 5-
aminoimidazole-4-carboxamide-1-D-ribofuranosyl-5' -monophosphate (ZMP). ZMP 
then activates AMPK which has been shown to be inhibited by CC and therefore 
served as a positive control of CC inhibition in the experiment. As shown in Figure 
16, both naringenin and AICAR stimulated AMPK phosphorylation and the action of 
both was inhibited by CC pre-treatment. This suggests that naringenin may have 
stimulated AMPK phosphorylation by causing an increasing in AMP: ATP ratio as 
well as suggesting that the stimulation of AMPK is not required for naringenin-
induced increase in glucose uptake. 
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Figure 16: Effects of CC on naringenin- and AICAR-stimulated AMPK 
phosphorylation. L6 myotubes were serum deprived and pre-treated with 25 /lM CC 
for 30 minutes followed by treatment with or without 100 /lM naringenin for 60 
minutes. After treatment total celllysates were prepared and resolved by SDS-PAGE 
and immunoblotted with specific anti-bodies that recognize phospho-AMPK 
(Thr172), and total-AMPK. 
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CHAPTER 5: DISCUSSION 
5.1 Naringenin significantly increases glucose uptake. 
Diabetes mellitus is a disease affecting the endocrine system which makes it a 
complex disease to treat. The dysfunction, inadequate insulin action to promote 
metabolic effects, has consequences on numerous tissues and functions. This is of 
course because the characteristics of the endocrine form of cellular communication 
are that it tends to be spread throughout the body, and affect many cells and tissues in 
diverse ways. Insulin is not an exception: it is involved in regulating metabolism and 
so acts on different target tissues and cell types, impacting glucose, lipid, and protein 
metabolism in an effort to coordinate the body to adopt the proper metabolism as 
needed (5,55,63,99,102). It is no wonder then that until the root dysfunction(s) can be 
treated, management of this disease is difficult. For type 1 diabetes, where the 
dysfunction is insufficient insulin, which can be corrected by administering insulin, 
the difficulty in management of the disease is in appropriately timing the treatment to 
approximate the normal physiological response that the body would have to the ever 
changing supply and demand of energy (110,123). In type 2 diabetes, where the 
dysfunction is an inadequate response to insulin, this difficulty is compounded in that 
the treatments available are in~ themselves approximations of insulin. There is no 
treatment that can do all that insulin would do in the body, in a healthy state. Yet 
another problem is that the dysfunction in type 2 diabetes is heterogeneous and 
therefore different people may need a different treatment regiment to address their 
particular points of deregulation (19.1,63,77,82,83,123). Therefore, the study of novel 
compounds that may mimic the effects of insulin on target tissues remains an 
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important area of research both for potentially finding more treatment options, as well 
as for increasing our knowledge of metabolic regulation in health and disease. 
One of the points of regulation that is disrupted in type 2 diabetes is peripheral 
glucose uptake. Skeletal muscle tissue is one of the targets of insulin and it is 
responsible for a major portion, ~80%, of glucose disposal in the post-prandial state 
(85). For this reason interventions that can improve glucose uptake in this tissue are 
of major interest. Naringenin has been reported to have antioxidant, antiproliferative, 
anticancer, and anti-inflammatory properties (1,22,92). Effects on glucose and lipid 
metabolism have also been reported. In vitro studies have shown that naringenin has 
an insulin-like effect to decrease basal oleate-stimulated apoliprotein B secretion in 
hepatocytes (7,8,9). In in vivo studies naringenin exhibited a hypoglycaemic effect in 
male wi star rats, and in streptozotocin-induced diabetic rats intraperitoneal 
administration of naringenin significantly decreased plasma glucose, triglycerides and 
total cholesterol levels (18,17,70). Furthermore naringenin has structural similarities 
with the extensively studied resveratrol which reportedly has antidiabetic properties 
both in vitro and in vivo (11,110,3.1,4,65,93,112.1). Therefore we examined the 
effects of naringenin on basal- and insulin-stimulated glucose transport in skeletal 
muscle. 
The rat L6 skeletal muscle cell line used in the present study is a well-
established model of skeletal muscle widely used in studies of insulin signalling and 
glucose transport. The L6 cells start off as myoblasts and can be induced to 
differentiate into myotubes (125). They express the GLUT1 , GLUT3 and GLUT4 
glucose transporters, the insulin receptor, IRS-I , PI3K, and Akt protein, and are 
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responsive to insulin (6,48,121,60). Acute insulin (100 nM) treatment causes a ~two­
fold increase in glucose uptake by the cell line within 15 minutes (58). There are 
currently no reported studies examining the effects of naringenin on skeletal muscle 
glucose transport in this or other cell lines. 
The present study present for the first time findings that naringenin stimulates 
glucose uptake in L6 skeletal muscle cells, demonstrating that naringenin has an 
insulin-like effect on skeletal muscle glucose uptake. This effect of naringenin is 
insulin independent as the cells were not treated with insulin. The level of naringenin-
mediated increase in glucose uptake is similar to that reached by insulin and the effect 
is time- and dose- dependent. However, the naringenin effect requires a longer 
incubation time to reach levels comparable to those reached by stimulation with 
insulin, naringenin requiring 120 minutes while insulin requiring only 30 minutes. 
This longer incubation time could be due to use of a different signalling cascade than 
that of insulin. This is plausible since other compounds (e.g. antidiabetic drug 
metforrnin) that stimulate glucose uptake appear to have different mechanisms of 
action than insulin (57). One possibility for using different mechanisms is differences 
in how compounds transmit their signal to the cell. N aringenin could either transmit a 
signal via interacting with molecules at the plasma membrane (e.g receptors) or it 
might enter the cell and directly affect signalling molecules within the cell. Using 
radioactively labelled naringenin EI Mohsen et al (21) showed that naringenin 
accumulates in tissues including the brain, lungs, heart, liver, spleen, and kidneys (in 
all tissues examined) and suggests that lack of complete recovery of the compound 
may be due to its accumulation in other tissues not tested such as muscle and adipose 
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tissue. Furthermore naringenin appears to interact with estrogen receptors which are 
located intracellularly (117,120). This implies that naringenin enters the cell but the 
exact mechanism of transport is unknown. The majority of flavonoids in their 
aglycone form are hydrophobic and therefore are suspected to cross the plasma 
membrane by simple diffusion. However in their glycosylated form they are more 
hydrophilic and would require transporters (62). Therefore it is likely that naringenin 
may utilize both passive diffusion and carrier-mediated transport as appears to be the 
case for the structurally similar resveratrol which has been shown to enter the cell by 
simple diffusion in hepatic cells and intestinal cells but may also involve carrier-
mediated transport in hepatic cells (45,67). Future studies could examine transport of 
naringenin in skeletal muscle and the time it requires by using radioactively labelled 
eH] naringenin as was performed for resveratrol in hepatocytes (67). 
In finding that naringenin enhances basal glucose uptake it was also found that 
naringenin has an additive effect on sub-maximal concentrations of insulin but not on 
maximal insulin concentrations. This suggests that naringenin may be a useful 
compound for the treatment of insulin resistance and future studies could examine 
this possibility in models of insulin resistance. The observation that naringenin tends 
to increase but does not si~ificantly change the level of glucose uptake with 
maximal insulin concentration could be due to naringenin treatment causing an 
almost maximum increase prior to addition of insulin, and therefore limiting the 
ability of insulin to cause any further effects on glucose uptake. It also suggests that 
the naringenin- and insulin-stimulated pathways may converge at some point. 
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The present study appears to be the only study that indicates the glucose 
uptake-stimulating effects of naringenin. Studies in 3T3-Ll adipocytes (40), U937 
monocytes (92), and T47D and MCF-7 breast cancer cells (39) all report that 
nanngenm inhibits basal (40,39,94) and insulin-stimulated (94) glucose uptake. 
Naringenin was also found to competitively inhibit glucose uptake in isolated rabbit 
intestinal and rat renal brush border membrane vesicles, and rat everted intestinal 
sleeves (71). These different effects of naringenin may be attributable to the use of 
different cell lines and different mechanisms of glucose transport and means of 
regulation employed by these cells. For instance, intestinal and renal glucose 
transport is largely mediated by the sodium-dependent glucose transporter, SGLTI 
(71), while glucose uptake in myotubes is transported via specific isofo~s of the 
sodium-independent GLUT glucose transporters. Other cells that respond to insulin 
and/or largely utilize GLUT transporters such as U937 monocytes, which express 
GLUTI and GLUT3, and MCF-7 cancer cells, which express GLUT4, may still have 
different regulation of glucose transport and thus respond differently to the 
compounds. Glucose transport in adipocytes is known to be more analogous to that 
of myotubes and therefore the different responses could also be due to differences in 
methodology. 
5.2 Elucidating the mechanism of naringenin action. 
In the present study we also report that like insulin, naringenin does not have a 
significant effect on glucose transport in myoblasts. Due to the properties of the L6 
line of differential expression of GLUTI and GLUT4 transporters between the 
myotube vs. myoblast stages (see section 3.3 in thesis) (58, 78) these results suggest 
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that the effect of naringenin-stimulated glucose uptake may modulate GLUT4 
transporter to the plasma membrane, GLUT4 intrinsic activity, or may inhibit GLUT4 
endocytosis or degradation thereby prolonging their half-life (56.1). Unlike GLUT4 
which is mainly expressed in the myotube stage, GLUTI levels are high in the 
myoblast stage and decline as the cells differentiate. Therefore if GLUTI is involved 
one would expect an increase in basal glucose uptake in myoblasts treated with 
naringenin. This was not observed. Besides GLUTI and GLUT4 the L6 also express 
the GLUT3 transporter which could also be involved in the naringenin-stimulated 
glucose uptake. This is unlikely since GLUT3 expression is similar in myoblasts as in 
myotubes (6,58) and so an increase in glucose uptake in naringenin-treated myoblasts 
would also be expected if that was the case. However this hypothesis is based on 
circumstantial evidence and so the effects of naringenin on the different GLUTs 
would need to be further examined. Some evidence of note to support evaluating 
modulation of GLUTs by naringenin comes from a study with the Canna indica, a 
plant traditionally used in Thai folk medicine to treat diabetes (97). An extract of this 
plant was found to contain several groups of flavonoids and to increase glucose 
uptake in L8 muscle cells, an effect that was also partially additive with insulin. 
Treatment with this extract increased the levels of cell surface GLUTI and GLUT4 
transporters as well as GLUTI expression. 
Future studies could look more directly at the effects of naringenin on the total 
and cellular localization levels of the GLUT isoforms. Total protein levels could be 
detected by preparing total cell lysates or total cell membranes and performing 
Western blot analysis using specific antibodies against GLUTl, GLUT3, and GLUT4 
N aringenin 86 
in the samples. The same could be done with isolated membrane fractions to examine 
changes in the redistribution of the GLUT isoforms intracellularly and at the plasma 
membranes (121). Additionally the effects of naringenin on GLUT translocation to 
the plasma membrane could be examined by detecting GLUT1myc and GLUT4myc 
cell surface levels in L6 myotubes expressing GLUT1myc and GLUT4myc, 
respectively. These cells express a GLUT isoform that is tagged with an exofacial 
myc epitope and the amount of GLUT1myc or GLUT4myc incorporated into the 
plasma membrane can be quantified immunologically (52,122). Besides the above 
studies it would also be important to examining the effects of naringenin on the 
stability of GLUT proteins at the plasma membrane and their intrinsic activity. 
L6 express estrogen receptors (ER) (50) and ERs may playa role in glucose 
homeostasis as mice lacking the a isoform of ER exhibit insulin resistance and 
impaired glucose tolerance (20). Recently Deng et al (20) presented data indicating 
that ERs are involved in the resveratrol-stimulated glucose uptake in muscle. Since 
naringenin appears to interact with ERs (117,120) it would seem valid to explore the 
significance of these receptors on naringenin-stimulated glucose uptake. 
Our data suggests that naringenin utilizes a different mechanism from insulin 
to increase glucose uptake since the increase in glucose uptake did not require Akt 
phosphorylation/activation. Akt is a serine/threonine kinase with three isoforms: 
Aktl, Akt2, and Akt3. The Akt2 isoform is implicated in the involvement of insulin-
stimulated glucose uptake and GLUT4 translocation (3,54,55). Full activation of Akt 
requires phosphorylation of two of its residues, Thr308 and Ser473 (55,114). As a 
result, phosphorylation of Akt at these residues has been generally accepted as an 
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indication of Akt activation. In our experiments naringenin treatment did not induce 
Akt phosphorylation at either of the residues. Previous studies with resveratrol show 
that increases in glucose uptake by resveratrol are also independent of Akt 
phosphorylation in L6 (in our lab) or C2Cl2 myotubes (88). Additionally, our data 
indicates that naringenin does not potentiate the insulin-stimulated Akt 
phosphorylation, indicating that its additive effect on insulin-stimulated glucose 
uptake is also Akt independent. This suggests that naringenin does not have insulin 
sensitizing properties but rather uses a different mechanism that combines with that 
produced by the insulin mechanism. 
In this study we also examined the potential role of PI3K in mediating the 
effects of naringenin, a signalling molecule involved in insulin-stimulated glucose 
uptake. To do this we used the specific and potent PI3K inhibitor wortmannin. 
Wortmannin is a microbial secondary metabolite that inhibits PI3K in an irreversible 
and non-competitively way (96). Our results suggest that the effect of naringenin on 
glucose uptake is PI3K dependent since inhibition of PI3K by wortmannin 
significantly inhibits the naringenin-stimulated glucose uptake. In our study we tested 
the efficiency of wortmannin to inhibit PI3K activity indirectly by examining Akt 
phosphorylation on insulin-tre~ted cells. The results indicate that wortmannin pre-
treatment completely abolishes the insulin-stimulated Akt phosphorylation, implying 
that wortmannin successfully inhibited PI3K activity in our experiments. Future 
studies- might directly examine the effects of naringenin on PI3K activity by 
performing a PI3K activity assay and measuring PIP3 production. PI3K involvement 
has also been reported for another effect of naringenin. Borradail et al showed that 
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nanngenm has an insulin-like effect of inhibiting apolipoprotein B secretion in 
hepatocytes which was partially inhibited by wortmannin (9). In addition the 
previously mentioned increase in glucose uptake by the flavonoid-containing extract 
of Canna indica was also PI3K dependent (97). Similar results have been shown with 
resveratrol which increased glucose uptake in L6 myotubes in a PI3K-dependent and 
Akt-independent way (in our lab), and PI3K involvement was apparent in the 
hypoglycaemic effects of resveratrol in vivo (16). Interestingly resveratrol-stimulated 
glucose uptake in C2C12 myotubes was found to be PI3K-independent (93). This 
discrepancy in results for resveratrol between the two skeletal muscle models could 
be due to differences between the two culture models. PI3K is particularly known for 
modulating GLUT4 translocation and while both L6 and C2C12 myotubes express 
these transporters (105,58,116) the C2C12 myotubes are reported to lack the insulin-
responsive vesicular compartments which appear to be necessary for proper GLUT4 
trafficking (116). The observation that the same polyphenol stimulates glucose uptake 
in what appears to be different mechanisms in cells that are both models of skeletal 
muscle may suggest that the polyphenol is capable of activating more than one 
pathway leading to glucose uptake. It should be noted that there are also reports in the 
literature that both naringenin .and resveratrol negatively regulate PI3K activity. In 
both, 3T3-Ll adipocytes and MCF-7 breast cancer cells, naringenin was found to 
inhibit PI3K (39,40), and resveratrol was found to inhibit PI3K-mediated glucose 
metabolism in b-cell lymphomas (25). One potential explanation for such a 
differences is tissue specific effects of the compounds. 
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Our finding that naringenin stimulates glucose uptake in a PI3K-dependent 
but Akt-independent manner is consistent with the present understanding of PI3K 
involvement in the insulin-stimulated glucose uptake. It is established that stimulation 
of the PI3K pathway by insulin is crucial for the insulin-stimulated glucose uptake. 
Inhibition of PI3K activity has been shown to completely abolish glucose uptake and 
GLUT4 translocation (15.1,55,91). However, although PI3K is required it is not 
sufficient for the insulin-stimulated glucose uptake. PI3K is activated by different 
hormones and growth factors but only activation of PI3K by some of these activators 
results in glucose uptake and GLUT4 translocation (31,48.1,112,113). And while in 
muscle both insulin and PDGF stimulate activation ofPI3K and Akt phosphorylation, 
only insulin induces Akt phosphorylation in adipocytes (112,113). In adipocytes PI3K 
appears to be required for GLUT4 translocation but insulin stimulation is additionally 
required to render the GLUT4 transporters functional (112). These experiments 
suggest that there may be a PI3K-independent pathway that cross talks with PI3K to 
mediate glucose transport by insulin. Likewise, this may be the case with the 
naringenin-stimulated glucose" uptake: naringenin may stimulate PI3K along with 
another signalling cascade, which may converge at some point. There are several 
isoforms of PI3K and becaus~ we did not observe Akt stimulation despite PI3K 
involvement it is possible that naringenin's action depends on a PI3K isofonn that is 
not involved in the stimulation of Akt. 
An alternative way of stimulating glucose uptake in skeletal muscle is via 
activations of AMPK, though the signalling pathway is still elusive and seems varied 
depending on the stimulus. We report that naringenin increases AMPK 
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phosphorylation in skeletal muscle cells. AMPK activation has also been implicated 
in mediating the antidiabetic effects of exercise, metformin, berberine, and resveratrol 
(13,28,84,35,126,110,119). AMPK is a protein kinase composed of three subunits, a, 
~, and y (28,118). Activation of AMPK requires phosphorylation at its Thr 172 residue 
(35,43,71) and this has been acknowledged as indicating activation. In mammalian 
cells AMPK acts as a sensor of change in cellular energy status, regulates numerous 
processes of cellular metabolism, integrates nutritional and hormonal signals in the 
peripheral tissues and the hypothalamus and mediates the effects of adipokines in 
regulating food intake, body weight and glucose and lipid homeostasis. With such 
varied metabolic effects it is not surprising that AMPK would have numerous ways of 
being activated. Activators of AMPK include an increase in AMP:ATP ratio 
(13,35,37,56), and its upstream kinases LKB1 (32,35) and CaMKK (35). 
PI3K has also been implicated in the activation of AMPK. Zou et al (126) 
found that activation of AMPK by metformin in cultured bovine aortic endothelial 
cells was PI3K dependent. They showed that pharmacological inhibition of PI3K by 
wortmannin or L Y294002 inhibited both AMPK phosphorylation and activity caused 
by metformin but did not inhibit AICAR-induced AMPK activity. In our study 
inhibition of PI3K by wortmaI1?in did not inhibit the naringenin-stimulated AMPK 
phosphorylation. As mentioned earlier we confirmed the potency of wortmannin as a 
PI3K inhibitor by testing its effectiveness on insulin-stimulated Akt phosphorylation 
and observing that this effect was abolished. This indicates that PI3K is not the 
mediator of naringenin-induced AMPK phosphorylation in L6 as it would seem based 
on the study of Zou et al with aortic endothelial cells. Our finding does not rule out 
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the possibility that AMPK and PI3K converge on some other point downstream of 
AMPK. 
Recently, research by Hou et al (46) showed that SIRTI is activated by 
polyphenols, which included resveratrol and a synthetic polyphenol, and mediates 
their effect to increase LKB 1 phosphorylation and AMPK activity in hepatocytes. 
They showed that inhibition of SIRTI phannacologically and genetically abolished 
the stimulating effects of polyphenols on AMPK. SIRTI has also been shown to 
deacetylate LKB 1 in HEK293T cells, which was associated with an increase in LKB 1 
activity and AMPK phosphorylation. Down-regulation of SIRTI on the other hand 
reduced phosphorylation of AMPK (66). SIRTI is a member of the sirtuin family of 
NAD+ -dependent protein deacetylases that are implicated to be involved in the 
beneficial biological effects of caloric restriction (CR) (47). One of the benefits of CR 
in animals appears to be a slight reduction in blood glucose levels and relative 
resistance to diabetes and resveratrol and other polyphenols appear to be CR mimetics 
(106). Resveratrol has been shown in an in vitro assay to directly stimulate SIRTI 
activity by ~ 13 fold compared to control, and several other polyphenols tested, 
including naringenin, also directly stimulated SIRTI activity, albeit only ~2-fold for 
naringenin (47). Based on th~ evidence that SIRTI appears to regulate AMPK 
activity including that induced by resveratrol as well as that polyphenols activate 
SIRTI we hypothesized that SIRTI might be involved in naringenin-stimulated 
glucose uptake via AMPK activation. In our study SIRTI inhibition by either 
nicotinamide or Ex527 does not reduce naringenin-stimulated glucose uptake, AMPK 
phosphorylation or LKBI phosphorylation suggesting that SIRTI does not playa role 
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III these effects of naringenin. It is possible that the role of SIRTI on AMPK 
activation is tissue specific since one study reported that in skeletal myoblasts AMPK 
is upstream of SIRTI (30). Our data also suggests that the observed AMPK 
phosphorylation does not seem to be mediated by LKB 1, since its phosphorylation 
was not increased by naringenin. Phosphorylation of LKB 1 occurs after it is activated 
and so it can be used as an indication of LKB 1 activation. However, phosphorylation 
is not required for activation of LKB 1 and so it weakens the validity of LKB 1 
phosphorylation as an indicator ofLKBl action (66). 
AMPK can also be activated by CaMKK. Phosphorylation of Thrl72 by 
this kinase is stimulated by a rise in calcium rather than an increasing AMP: ATP 
ratio (35). Although muscle-specific knockouts of LKBI suggest that the calcium-
mediated pathway does not have a significant contribution in skeletal muscle, the 
contraction-induced glucose transport in skeletal muscle cells is believed to be in part 
mediated by increased cytosolic calcium levels and activation of the CaMKK-
dependent AMPK, as is suggested to be the case for mouse skeletal muscle during 
mild tetanic contractions (35,49). It has also been shown that oxYtocin-stimulated 
glucose uptake in C2C12 cells uses a mechanism that involves activation of CaMKK 
and AMPK (69). Therefore this kinase may be a mediator of AMPK activation in 
muscle by some stimuli and its involvement in naringenin-stimulated glucose uptake 
was examined. We found that inhibition of CaMKK by STO-609 does not inhibit 
naringenin-stimulated glucose uptake, indicating that this kinase is not involved in 
this action of naringenin. The effects of STO-609 on naringenin-stimulated AMPK 
phosphorylation was not examined by us so it is possible that CaMKK mediates 
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naringenin-stimulated AMPK phosphorylation but that this stimulation of AMPK is 
not involved in naringenin-stimulated glucose uptake. Therefore future studies could 
examine whether inhibition of CaMKK abolishes AMPK phosphorylation induced by 
naringenin. Additionally, measurements of intracellular calcium would shed light on 
whether naringenin induces high intracellular calcium level, which could activate 
CaMKK. 
Another way of activating AMPK is by an increase in AMP:ATP ratio 
(13,35,37,56). Therefore we examined whether inhibition of AMPK by compound C 
(CC) would have an impact on naringenin-stimulated glucose uptake. Our results 
indicate that compound C does not have an effect on naringenin-stimulated glucose 
uptake. Thus far we do not have evidence suggesting that AMPK mediates the 
naringenin-stimulated glucose uptake and although the results seem to suggest against 
it the possibility cannot be ruled out. CC is an A TP-competitive AMPK inhibitor. 
Since AMP and ATP competitively bind to the same site on AMPK (51), the effect of 
CC in the cell would seem to decrease the chance of AMP binding to the AMPK site 
thereby mimicking a state of decreased AMP:ATP ratio. The mechanism of CC 
makes it an imperfect AMPK inhibitor since AMPK is activated by a variety of 
stimuli some of which do not. alter the AMP:ATP ratio (13,126,111). Besides the 
aforementioned CaMKK (35), metformin is another example reported to stimulate 
AMPK phosphorylation without requiring an increase in AMP:ATP (126). Metformin 
acts as an inhibitor of mitochondrial complex I of the respiratory chain and therefore 
may cause a decrease in ATP production. However, some studies report that the 
activation of AMPK by metformin occurs without affecting the AMP:ATP ratio and 
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Zou et al found that ONOO- activates AMPK without changes in cellular A TP or 
AMP levels (126). In light of this information it was important to determine whether 
CC was an effective inhibitor of AMPK in the case of naringenin. Our data suggests 
that CC is effective in inhibiting naringenin-stimulated AMPK phosphorylation. 
These results suggest that naringenin stimulates AMPK phosphorylation but this 
effect is not necessarily required for naringenin to stimulate glucose uptake. Future 
studies could use small interference RNA (siRNA) to silence AMPK protein 
expression to examine with more clarity if AMPK has a role in naringenin-stimulated 
glucose uptake. This approach has been used by Konrad et al (61) to examine the 
mechanism of antidiabetic drug troglitazone on glucose transport in the L6 line. 
Alternatively a dominant-negative (DN) AMPK could be used that has a mutation in 
the a-subunit resulting in a kinase dead form of AMPK as was performed by Mu et al 
(81). 
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Figure 17: Schematic of results summary. Naringenin stimulates glucose uptake in L6 
myotubes. The effects of naringenin are PI3K-dependent but Akt-independent. 
Naringenin stimulates AMPK phosphorylation. The effects of naringenin on glucose 
uptake and AMPK stimulation are SIRTl independent. The naringenin-stimulated 
glucose uptake is not inhibited by CaMKK or AMPK inhibition. Activation of AMPK 
by naringenin may not be necessary for its stimulatory effect on glucose uptake. 
5.3 Limitations and Future Directions 
Future studies could utilize siRNA to inhibit AMPK expression in L6 skeletal 
muscle or DN AMPK to determine more conclusively the AMPK molecule's role in 
naringenin-mediated glucose uptake. The effect of naringenin on GLUTl, GLUT3, 
and GLUT4 levels and activity could be examined. This study focused on the in vitro, 
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acute effects of naringenin in L6 skeletal muscle cells but further research could 
extend the study of naringenin to examine chronic effects of naringenin, effects on 
other insulin target cells and in vivo, as well as in vitro and in vivo models of insulin 
resistance. Also, future studies could examine how naringenin is transported into 
skeletal muscle cells. 
The preset study found that pretreatment with wortmannin partially inhibited 
naringenin-stimulated glucose uptake which may indicate that PI3K may be involved 
in naringenin's action. There are different isoforms of PI3K and the class I isoform 
stimulates Akt phosphorylation which leads to glucose uptake. Since Akt 
phosphorylation was not stimulated by naringenin it is possible that another PI3K 
isoform may be involved. Another target of PI3K that is known to lead to glucose 
uptake is PKC and future studies could examine this protein's involvement in 
naringenin-stimulated glucose uptake. A major limitation of the present study is that 
wortmannin at a 1 ~M was used to examine the involvement of PI3K. This 
concentration of wortmannin has been used previously by others in skeletal muscle 
culture including the L6 cell line (119.1, 124.1). However, at this concentration 
wortmannin is not very specific and not only inhibits all PI3K isoforms, which all 
have an IC50 values in the nm r~nge, but also several other proteins including mTOR, 
DNA-dependent protein kinase, and myosin light chain kinase (16.1, 60.1). Therefore 
it cannot be concluded that PI3K is involved, and studies directly examining PI3K 
activity would be beneficial to determine whether naringenin increases PI3K activity. 
A limitation in the present study is that glucose uptake was assessed only 
using 2-eH]deoxy-D-glucose (2DG) while 3-0-[methyPH]-D-glucose was not used. 
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Once inside a cell 2DG can be phosphorylated by hexokinase although it cannot be 
further metabolized in glycolysis. Because of this, hexokinase activity can influence 
the rate of 2DG uptake by altering the concentration gradient for 2DG entry and so 
changes in glucose uptake measurements could be due to changes in glucose 
facilitated transport and/or glucose phosphorylation rate. In the present study the 
observed changes in glucose uptake levels should indicate changes in facilitated 
transport since the L6 cells were incubated with 2DG for 10 minutes and it has been 
reported by others (56.2) that for the first 10 minutes 2DG uptake into L6 cells is 
limited by transport. Nevertheless, the possibility exist that 2DG uptake levels are not 
only determined by glucose transport. The use of 3-0-[methyPH]-D-glucose, which 
does not get phosphorylated, would be useful to confirm that the naringenin-
stimulated glucose uptake observed in the study is due to increased 2DG transport 
rather than increased phosphorylation of2DG (56.2). 
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APPENDIX I: 
The results in this thesis, that naringenin stimulates glucose uptake in L6 
skeletal muscle, are in contrast with several studies that indicate that naringenin 
inhibits glucose uptake. As mentioned earlier in the discussion section of the thesis, 
these contrasting results could be due to tissue/cell type specific effects or to 
differences in methodology. Upon examination of the method sections of these 
studies reporting inhibitory effects of naringenin I observed that all three follow a 
protocol of including the test compounds in a buffer to which the radioactively 
labeled glucose is then added. In the glucose uptake assays I followed a protocol in 
which the test compounds were removed by washing before the uptake assay was 
performed. Some of my last experiments examined the effects of incubating 
naringenin in the glucose uptake buffer on glucose transport. This preliminary data is 
presented here. The results indicate that when myotubes are treated with naringenin 
and prior to performing the glucose uptake assay the media containing naringenin is 
removed, the result is an increase in glucose uptake. However, if the glucose uptake 
assay is performed in the presence of naringenin, the result is a prevention of the 
increase in glucose uptake of naringenin-treated cells originally observed when 
naringenin was excluded from t!Ie uptake buffer. This inhibition is so great that it not 
only abolishes the increase in glucose uptake but also inhibits it below basal glucose 
uptake. Furthermore, this inhibition is not due to an osmotic effect since neither 
exposure to sucrose or mannitol in the same concentration as naringenin affected 
basal or naringenin-stimulated glucose uptake (see Figure and details at end of 
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Appendix I). These preliminary results suggest that naringenin may be an inhibitor of 
glucose uptake and further research needs to be performed to explore this possibility. 
Besides naringenin, similar contrasting reports are present for the effects of 
other flavonoids and resveratrol on glucose uptake in vitro. On one hand polyphenols 
are reported to stimulate glucose uptake in several cell lines, on the other, many of the 
same polyphenols are reported to inhibit glucose uptake. Resveratrol has been shown 
to stimulate glucose uptake in two skeletal muscle culture models, L6 and C2C12 
(11,93); to have no significant effect on glucose uptake in human diffuse large B-cell 
lymphomas 25); and to inhibit glucose uptake in human transformed myelocytic cells 
(U937 and HL-60) (94) and ovarian cancer cells (64). The polyphenoliclflavonoid 
containing extract from Canna indica has been reported to increase glucose uptake, 
GLUTI and GLUT4 content at the plasma membrane, and GLUTI expression in L8 
muscle cells (97). Also, the flavonoids kaempferol and quercetin are reported to 
increase insulin-stimulated glucose uptake in 3T3-Ll cells (26). On the other hand, 
there are numerous reports indicating that flavonoids are inhibitors of glucose 
transport. Flavonoids are reported to inhibit glucose uptake in porcine jejunum brush-
border membrane vesicles (quercetin monoglucosides) (15), isolated rat adipocytes 
(myricetin, quercetin, catech~n-gallate) (109), human erythrocytes (numerous 
flavonoids) (76), Xenopus laevis oocytes (numerous flavonoids) (62), and MC3T3-
G2/PA6 adipose cells (numerous flavonoids) (89). Interestingly quercetin is reported 
to have varied effects between a model of adipocytes and isolated rat adipocytes (26, 
62). 
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The methods sections of these reports consistently exhibit the protocol 
difference in the glucose uptake assays between the studies that indicated stimulatory 
vs. inhibitory effects of polyphenols, as was shown for naringenin. Among the studies 
where similar methods were used the studies that showed a stimulatory effect 
followed a protocol in which the test compounds were removed by washing before 
the uptake assay was performed (11,26,97). On the other hand, the studies reporting 
inhibitory effects followed a protocol which included the test compounds in a buffer 
to which the radioactively labelled glucose was then added (40,39,94,71,95,62,89). A 
few of the studies did not have sufficient information to determine which protocol 
was used (93,64). A major difference between the protocols is the removal of the 
potential inhibitor before performing glucose uptake measurements, thus removing 
the inhibitory stimuli. 
Several of the studies that indicate inhibitory effects on glucose transport 
suggest that the nature of the inhibition is via inhibition of the glucose transporters 
and not necessarily only through regulation. In the myelocytic cells the inhibition by 
resveratrol was competitive and also inhibited dehydroascorbic acid uptake, which is 
known to occur via GLUTI and GLUT3 isoforms (94). To elucidate whether the 
means of inhibition of glucost? and dehydroascorbic acid uptake is by blocking the 
GLUT transporters the effects were also tested in Chinese hamster ovary (CHO) cells 
overexpressing GLUTI or GLUT3. Overexpression of either of these isoforms 
increased glucose and dehydroascorbic acid uptake and resveratrol dose-dependently 
inhibited both of their uptakes (94). Quercetin monoglucosides were also shown to 
competitively inhibit SGLTI glucose uptake in porcine jejunum brush-border 
Naringeninl20 
membrane vesicles (15). Some studies have looked specifically at the effects of 
flavonoids on glucose transporters in order to identifY the means by which flavonoid 
glucosides are transported into cells (15). Unlike their aglycone forms, which are 
hydrophobic, flavonoid glycosides are hydrophilic and need transporters to cross the 
plasma membrane. The glucose transporters were considered candidates for this 
action. In this respect Kottra and Daniel (62) examined the effects of flavonoids with 
and without attached glucose residues on the sodium-dependent SGLTI transporters 
in Xenopus laevis oocytes. By testing transport currents generated by different 
flavonoids in Xenopus laevis oocytes expressing SGL T I they showed that none of the 
flavonoids tested, including naringenin, are substrates for SGLTI nor are they 
transported through it. However, the flavonoid glycosides as well as some of the 
aglycones were effective competitive inhibitors of SGLTI and had high affinity for 
the transporter, the degree of which was structurally dependent. The aglycone form of 
naringenin was a non-competitive potent inhibitor, while its glycosylated form was 
competitive. The researchers speculated that flavonoids can bind the transporter with 
either its sugar moiety or another part of the molecule (62). 
Evidence also exists for flavonoids interacting with some isoform of the 
GLUT transporter family. I~ Xenopus laevis oocytes expressing the GLUT2 
transporter different classes of flavonoids were found to inhibit GLUT2-mediated 
glucose transport (from 62). Several flavonoids have also been shown to inhibit 
GLUTI-mediated glucose uptake through what appears to be a direct interaction with 
it (109). The study by Strobel et al (109) in isolated rat adipocytes showed that 
several flavonoids competitively inhibited glucose uptake. As one part of their study 
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they developed a three-dimensional molecular comparative model of the GLUT4 
transporter in order to examine molecular dynamics of flavonoid interaction with 
GLUT4. Their simulation with flavonoids revealed a direct, non-bonded interaction 
with the transporter, as was found for D-glucose (109). 
If polyphenols are in fact interacting with glucose transporters in a way that 
inhibits glucose transport, why the contrasting results indicating that flavonoids 
increase glucose uptake? An interesting hypothesis presents itself. If certain 
polyphenols bind to glucose transporters and potently inhibit their ability to transport 
glucose then this action could mimic a state of glucose deprivation for the cells. 
Glucose is known to regulate its own transport and a state of glucose deprivation is 
known to have stimulatory effects on glucose transport in muscle cells, cultured 
fibroblasts, cardiocytes, adipocytes, and glial cells (121, 57, 60). In L6 muscle cells 
chronic and acute glucose deprivation was shown to stimulate glucose uptake above 
basal, resulting in a 4-fold increase in glucose uptake within 2 hours that remained 
elevated for over 22-hours (121). The results suggest that glucose deprivation causes 
GLUTI translocation to the plasma membrane and activation of its intrinsic activity, 
followed by an increase in the rate of GLUTI transporter mRNA transcription and 
protein synthesis in the chron~c glucose deprivation state (121). In another study 
glucose deprivation was also shown to increase GLUT4 levels in the plasma 
membrane (60). In this respect an important weakness of my preliminary data is that 
the glucose uptake assay was not performed under in vivo-like conditions. The uptake 
assay is performed with only 10 ~M 2-deoxy-D glucose while prior to, when the cells 
are incubated with naringenin for two hours, the culture media contains 5 mM of 
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glucose to mimic an in vivo condition. Therefore under these conditions the relative 
low quantity of naringenin to glucose may not adequately inhibit glucose uptake to 
induce a glucose deprived-like state. This concern points to the preliminary nature of 
the present results and the need to perform experiments with naringenin in various 
glucose concentrations to determine the effect on Km and Vmax of glucose uptake 
and the potency of naringenin as an inhibitor. 
One explanation of why glucose restriction (or glucose transporter 
inhibition) leads to improved glucose uptake may be that it creates a mild stress on 
the cells which causes them to induce a survival response. This is consistent with the 
Hormesis hypothesis that aims to explain the health benefits of caloric restriction 
(CR) (106). This hypothesis states that CR confers health benefits by creating a 
mildly stressful condition within an organism that stimulates a survival response 
which alters metabolism and activates defence mechanisms against aging (106, 47). 
Notably, one of the health benefits of caloric/glucose restriction has been on type II 
diabetes by improving insulin sensitivity and maintaining reduced blood glucose 
levels" Animals on caloric restriction show lower blood glucose levels and appear to 
be relatively resistant to the development of diabetes (106). This appears to be due to 
an increase in glucose uptake in skeletal muscle and fat pads resulting from an 
increase in GLUT4 at the plasma membrane (106). The Hormesis hypothesis ofCR is 
also the bases for understanding why polyphenols mimic the beneficial effects of CR. 
Polyphenols, which are produced by plants under stress, have been shown to activate 
stress-response pathways in yeast, worms and flies, and it is suspected that these and 
other organisms have evolved to recognize these molecules as stress signals 
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indicative of an unfavourable environment and adopt changes to enhance their 
survival (106). Thus it is suspected that polyphenols may stimulate the same inherent 
defence mechanisms as CR. This was suggested to be the case for resveratrol in a 
study by Howitz et al (47) who showed that resveratrol extended lifespan of 
Saccharomyces cerevisiae, as was reported for caloric restriction, but glucose 
restriction did not result in extension of lifespan of resveratrol-treated cells (47). 
Furthermore, there are several signalling molecules including SIRTI and AMPK, that 
are reported to be modulated by both polyphenols and CR (30, 88). 
In summary, the literature indicates that polyphenols, specifically different 
subclasses of flavonoids and resveratrol, possess both stimulatory and inhibitory 
effects on glucose transport. This could be due to tissue specific effects but there also 
appears to be a slight but consistent difference in the protocol used in the glucose 
uptake assay. The significance of this difference needs to be further examined, 
particularly in an in vivo-like glucose state. In some cases the inhibitory effects of 
flavonoids appear to be due to their interaction with and blockade of the glucose 
transporters, which gives credence to the importance of the difference in the protocol 
(i.e. inclusion vs. exclusion of the compounds in the uptake buffer). Although 
seemingly contradictory, initia! inhibition of glucose uptake by these compounds may 
not necessarily be counterintuitive since glucose deprivation stimulates glucose 
uptake in a variety of cell types. The possibility that certain polyphenols may create a 
state of glucose restriction and in tum activate a counter-acting stress response seems 
feasible since mild stress induction, which is the bases of the Hormesis hypothesis, 
explains the health benefits of caloric restriction, and because some polyphenols are 
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considered mimetics of caloric restriction, as evidenced by their ability to mimic the 
same responses and modulate some of the same signalling molecules as caloric 
restriction. 
Effects of naringenin incubation with glucose uptake buffer on glucose uptake. 
In following the glucose uptake protocol used in our lab we remove the media 
with our test compounds then wash out any residue before incubating with the 
radioactively labeled glucose uptake buffer. Because the uptake buffer does not 
contain the test compounds in it, in this case naringenin, it is important to examine 
what direct effects naringenin would have on glucose transport. To tests this 
myotubes were treated with or without 100 JlM naringenin for 2 hours. At end of 
treatments eH] 2-deoxy-D glucose uptake was performed but some cells were 
incubated with regular glucose uptake buffer while others were incubated with the 
glucose uptake buffer supplemented with 100 JlM naringenin. There was also a 
possibility that any differences in glucose uptake could be due to either a specific 
action of naringenin or to an osmotic effect created by naringenin. Therefore to 
control for the osmotic effect some groups of cells were incubated with an uptake 
buffer supplemented with 100 JlM of sucrose or mannitol. Mannitol is a sugar alcohol 
used to control for osmolaritJ'.. Sucrose was used since as a disaccharide it is not 
absorbed by cells which do not have transporters to aid across the plasma membrane. 
One group of cells was also incubated with glucose uptake buffer supplemented with 
the vehicle (0.1 % ethanol). 
As before, treatment with 100 JlM nanngemn for 2 hours followed by 
incubation in regular buffer led to a significant increase in glucose uptake (189±5.2% 
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of control, p<O.OOl). However, treatment with naringenin followed by incubation 
with naringenin-supplemented uptake buffer led to abolishment of glucose uptake 
originally observed which was also significantly below basal levels (56±7.4% of 
control, p<O.OOl and p<0.05, respectively). Naringenin-supplemented uptake buffer 
significantly inhibited basal glucose uptake of untreated cells (32± 4.9% of control, 
p<O.OOl). Treatment with 1 00 ~M sucrose or mannitol for 2 hours followed by 
incubation with normal uptake buffer had no significant effect on glucose uptake 
(95±3.4% and 95±11.8% of control), nor did the sucrose- or mannitol-supplemented 
uptake buffer have an effect on naringenin-stimulated increase in glucose uptake or 
basal levels (169±4.9%, 1 55±8.4%, 99±2.3%, and 113±13.3% of control, 
respectively). These results suggest that naringenin has a specific inhibitory effect on 
glucose transport into myotubes. 
It is interesting to consider that differences in technique of eH] 2-deoxy-D 
glucose uptake measurements might explain differences in findings that naringenin, 
or any other compound for that matter, is an inhibitor of glucose uptake in some 
studies and an activator in others as it was here. As an aside it was interesting to 
examine if the same effect would be observed with resveratrol and our finding 
suggest that resveratrol-suppl~mented uptake buffer also has an inhibitory effect on 
glucose uptake. 
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Effects of naringenin in uptake buffer on glucose uptake. L6 myotubes were serum 
deprived and pre-treated with or without 100 11M naringenin, sucrose, or mannitol for 
2 h. At end of treatments eH] 2-deoxy-D glucose uptake was performed with either 
normal uptake buffer, 100 11M naringenin-suppleinented uptake buffer, 100 11M 
sucrose-supplemented uptake buffer, 100 11M mannitol-supplemented uptake buffer, 
or 0.1 % ethanol supplemented uptake buffer. Results are the mean ± SE of 3-4 
experiments expressed as percent of control. *p< 0.05, ** p<O.Ol, ***p<O.OOI 
compared to untreated contr9l. ###p<0.001 compared to naringenin treated and 
incubated in normal buffer. C = control, Ng = naringenin treated, S = sucrose treated, 
M = mannitol treated, Ngb = naringenin-supplemented uptake buffer, Sb = sucrose-
supplemented uptake buffer, Mb = mannitol-supplemented uptake buffer, EtOH = 
ethanol-supplemented uptake buffer. 
